TRAIL-induced Apoptosis in Populations of Colon Cancer Cell Lines under Various Cultivation Conditions by Nevařil, Leonard
Charles University in Prague 
Faculty of Science 
Department of Cell Biology 
 
 
 
 
 
 
DIPLOMA THESIS 
 
 
 
 
TRAIL-induced Apoptosis in Populations of Colon Cancer Cell 
Lines under Various Cultivation Conditions 
 
 
 
Leonard Nevařil 
 
 
 
 
 
 
 
 
Prague 2009 
Supervisor: RNDr. Ladislav Anděra, CSc. 
 
Department of Cell Signaling and Apoptosis 
Institute of Molecular Genetics AS CR, v. v. i. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I hereby declare that this diploma thesis is my own work and effort. I have 
referenced all literature sources and I have worked under supervision of RNDr. Ladislav 
Anděra, CSc. 
 
 
 
Leonard Nevařil  
 2
This study was carried out in the Laboratory of Cell Signaling and Apoptosis, 
Institute of Molecular Genetics AS CR, v. v. i., and was supervised by RNDr. Ladislav 
Anděra, CSc. 
 
Project was financially supported by the Center of Molecular and Cellular Immunology 
(1M6837805001) and in part by the institutional grant AV0Z50520514. 
 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgments 
 
I would like to thank RNDr. Ladislav Anděra, CSc. for supervision of my diploma 
thesis, patience and valuable advices. Further I thank all members of the Laboratory of Cell 
Signaling and Apoptosis for maintaining nice and inspiring work environment and 
numerous practical tips that enhanced my working skills. I thank especially to Mgr. Michal 
Koc, PhD for self-sacrificing help with lentiviral vectors. I thank also Prof. Karel Smetana 
Jr. and his co-workers from the Institute of Anatomy, First Faculty of Medicine, Charles 
University, Prague for rendered biological material and very helpful attitude.  
Last but not least, my very special thanks go to my family and my partner Helena 
Chmelová for absolute and never-ending support during the time of my studies. 
 4
Abstract  
Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) is a cytokine 
of TNF family, which participates in the non-exclusive regulation of survival and 
proliferation of mainly hematopoietic cells. Shortly after its discovery it also brought 
significant attention as specific and potent inducer of apoptosis of cancer cells of various 
origins, and since then it has been investigated as a potential novel anti-tumor therapeutics.  
Recently, cancer stem cells (CSCs) were suggested to be a distinct subset of tumor cells 
that could be responsible at least in some tumors for their sustainment, recurrence and drug 
resistance. These cells in the “hierarchic” model of tumorigenesis thus represent an 
important and attractive target for efficient tumor therapy.  
In this study we use several colorectal adenocarcinoma cell lines as an experimental 
model for the analysis of CSC-prone cultivation conditions on TRAIL-induced apoptosis of 
these cells. For enrichment of eventual cancer stem cells we cultivated cell lines in a serum-
free medium, originally developed for cultivation of neural stem cells, and assessed the 
expression of putative CSC markers CD133 and ABCG2 by flow cytometry (FACS). 
Simultaneously, we tested the expression of TRAIL receptors and susceptibility to TRAIL-
induced apoptosis in these cells. We observed correlation between appearance of stem cell-
like signs (spheroid formation, expression of CD133) and increased resistance of these cells 
to TRAIL-induced apoptosis. Profiling of surface proteins revealed that compromised 
apoptosis was not inherent in expression of death receptors, since these were mostly 
upregulated after serum-free cultivation. 
Recently it has been reported, that fibroblasts isolated from tumor stroma could 
induce de-differenitated, stem cells-like phenotype in normal human keratinocytes and thus 
these stromal cells represented an attractive tool for the analysis of their effect on TRAIL-
induced apoptosis of co-cultivated tumor e.g. colon cancer cells. In our initial attempt we 
analyzed effect of both normal skin and tumor stroma-derived (basal cell carcinoma, spinal 
cell carcinoma and benign fibrous histiocytoma ) fibroblasts on TRAIL-induced apoptotic 
signaling in selected colorectal adenocarcinoma cell lines. We observed no unequivocal 
effect of either stromal or normal fibroblasts on TRAIL-induced apoptotic signaling in two 
co-cultivated colon cancer cell lines HCT 116 and DLD-1. We cannot however exclude 
possible cancer cell-type specific influence of stromal cells on TRAIL-induced apoptosis 
and thus further analysis using different cancer cell lines is required. 
 
 
 
 
 
 
 
Key words 
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List of abbreviations  
aa   amino acid 
ABB   annexin V-binding buffer 
ABCG2  ATP-binding cassette G2  
AIF   apoptosis inducing factor 
Apaf-1   apoptosis protease activating factor-1 
Apo-2   death receptor 4/TRAIL receptor 1 
ATP   adenosine 5’-triphosphate 
B cell   B lymhocyte    
Bad,   Bcl-2 antagonist of cell death  
Bak   Bcl-2 antagonist killer 
Bax   Bcl-2-associated X protein 
Bcc   basal cell carcinoma 
Bcl-2   apoptosis regulatory protein discovered in B-cell lymphoma 
Bcl-xL   apoptosis regulatory protein allied to Bcl-2 
Bfh   benign fibrous histiocytoma 
BH   Bcl-2 homology domain 
Bid   BH3-interacting domain death agonist 
Bik   Bcl-2-interacting killer 
Bim   Bcl-2-like 11 protein 
Bmf   Bcl-2-modifying factor 
BMP   bone morphogenetic protein 
Bok   Bcl-2-related ovarian killer 
CD   cluster of differentiation 
CMTPX  CellTracker Red dye 
CSC   cancer stem cell 
C-terminus  carboxy-terminus/COOH-terminus 
CAF   cancer-associated fibroblast 
CARD   caspase recruitment domain 
CRD   cysteine-rich domain 
Cys   cysteine 
CXCR4  receptor of SDF-1 
cyt c   cytochrome c 
Da; kDa  Dalton (molecular mass unit 1Da ≈ 1.6605×10−27kg); kiloDalton 
DC   dendritic cell 
DcR   decoy receptor 
DD   death domain 
DED   death effector domain 
DIABLO  direct IAP-binding protein with low pI/murine homolog of Smac  
DISC   Death-Inducing Signaling Complex 
DMEM  Dulbecco’s modified Eagle’s medium 
DNA   deoxyribonucleic acid  
DP5   see Hrk 
DR   death receptor 
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ECM   extracellular matrix 
e.g.   for example  
EGF   epidermal growth factor 
EMT   epithelial-mesenchymal transition  
ERK   extracellular signal-regulated kinase 
EST   expressed sequence tag 
etc.   et cetera  
FADD   Fas-associated death domain (adaptor protein)  
FACS   Fluorescence-activated cell sorting 
FasL   Fas ligand  
FBS   fetal bovine serum 
bFGF   basic fibroblast growth factor 
FITC   fluorescein isothiocyanate 
FLICE   FADD homologous ICE-like protease/caspase-8 
FLIP   FLICE-like inhibitory protein  
GPI   glycosylphosphatidylinositol 
His   histidine 
Hrk   hara-kiri/Bcl-2-interacting protein/DP 5 
i.a.   inter alia 
IAP   inhibitor of apoptosis protein 
ICE   caspase-1 
IFN   interferon 
IMDM   Iscove's Modified Dulbecco's Media 
JNK   Jun N-terminal kinase  
mAb   monoclonal antibody 
MAP   mitogen-activated protein kinase 
Mcl-1   myeloid cell leukemia protein-1    
mDR-5  murine death receptor-5  
MOMP  mitochondrial outer membrane permeabilization 
mRNA   messenger ribonucleic acid 
mTRAIL  murine Tumor-necrosis factor-Related Apoptosis Inducing Ligand 
N-terminus  amino-terminus/NH2-terminus 
NF-κB   nuclear factor κB  
NK; NKT   natural killer cell; natural killer T cell 
Noxa   BH3-only member of the Bcl-2 family 
NS-Ac   serum-free medium (complete) 
OPG   osteoprotegerin 
p53   transformation-related protein 53 
PBS   phosphate-buffered saline 
PCD   programmed cell death 
PE   phycoerythrin  
PI   propidium iodide  
PI3K   phosphatidylinositol 3-kinase 
Puma   p53-upregulated modulator of apoptosis 
RANK   receptor activator of NFκB 
RANKL  receptor activator of NFκB ligand 
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RFP   red fluorescent protein 
RIP   receptor-interacting protein 
RLU   relative luminescence unit  
ROS   reactive oxygen species 
RPMI   cultivation medium (RPMI 1640) 
Scc   spinal cell carcinoma  
SDF-1   stromal cell-derived factor 1 
siRNA   small interfering ribonucleic acid 
Smac   second mitochondria-derived activator of caspase 
SRP   signal recognition particle 
T cell   T lymphocyte 
TIC   tumor initiating cell 
tBid   truncated form of BH3-interacting domain death agonist 
TH1   helper T lymphocyte type 1 
TH2   helper T lymphocyte type 2 
THD   TNF-homology domain 
TNF-α   Tumor-necrosis factor-α 
TNFR   Tumor-necrosis factor receptor 
TNFSF 10  Tumor-necrosis factor superfamily member 10 
TRADD  Tumor-necrosis factor receptor-associated death domain protein 
TRAIL  Tumor-necrosis factor-Related Apoptosis Inducing Ligand 
TRAIL-R  Tumor-necrosis factor-Related Apoptosis Inducing Ligand receptor 
WIPO   World Intellectual Property Organisation 
XIAP   X-linked inhibitor of apoptosis protein 
σ   standard deviation 
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I. Introduction 
Metazoan ontogeny represents a sequence of tightly regulated processes leading to a 
stable architecture of the adult body. In case of sexually reproducing organisms, this 
sequence starts at zygote, which further divides in a well organized manner and constitutes 
primitive cells of the embryo. As these cells further perpetuate themselves and generate 
differentiated progeny, levels of complexity are being added eventually leading to highly 
complex functional tissues and organs of the newly arising individual. Most likely it is 
cellular hierarchy and polarization through which the information of a body plan is 
ultimately being executed at all aforementioned levels of development (Wodarz, 2002). Not 
only this idea is intuitive, it has been supported by mathematical modeling that hierarchy 
applies as a background principal essential for the maintenance of tissue homeostasis, 
suggesting its importance for both developing and adult organism (Paulus et al., 1992). A 
crucial question remains as to how the hierarchy is initiated and namely whether its 
constitution is a onetime or recurrent process during the lifespan of an individual. 
By contrast, it is probable that cancer is a group of diseases emerging directly from 
abusing certain developmental principles. Despite of many hollow places in our basic 
understanding of cancerogenesis, its ultimate lethality is based on unregulated cell growth 
and crippled tissue homeostasis. In other words, the mechanisms responsible for 
maintenance of cell counts must be unbalanced. One such mechanism, apoptosis, has been 
in focus of cancer research since its discovery more than century ago. This form of 
programmed cell death is an evolutionary conserved process that is in multicellular 
metazoans and plants required for elimination of no-longer needed or dangerous (e.g., 
infected or malignant) cells (Joza et al., 2002). Unlike necrosis, apoptosis relies on firmly 
regulated cascades of finely-tuned events that finally lead to organized destruction of the 
dying cell, relatively gentle to the surrounding tissue (Saraste and Pulkki, 2000).   
Combining the rapidly growing developmental perception of cancer that has 
recently concentrated around the so called “cancer stem cell” (CSC) hypothesis with the 
fact that apoptosis is strongly involved also in fundamental developmental processes, it is a 
tempting idea to search for signals that could eventually initiate apoptosis in hierarchically 
outstanding cells.  
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Several lines of evidence have recently hinted that Tumor-necrosis factor-Related 
Apoptosis Inducing Ligand (TRAIL) is a promising molecule for selective killing of 
cancerous cells. For possible consequences of TRAIL with anti-tumor/anti-metastatic 
immune surveillance (Grosse-Wilde et al., 2008), we decided to investigate the sensitivity 
of differentially cultured colon cancer cells to TRAIL-induced apoptosis. 
   
Following aims of the study were set: 
 
1. To characterize given colon cancer cell lines (morphology, sensitivity to 
TRAIL-induced apoptosis, expression of surface markers) depending on various 
cultivation conditions   
 
2. To asses phenotype of colon cancer cell lines in relation to cancer stem cell 
hypothesis 
 
3. To develop co-cultivation design for investigation of direct influence of tumor 
stromal fibroblasts on cancer cell phenotype 
 
4. To assess the potential of TRAIL as a anti-CSC agent 
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 II. Review of the literature 
II.1 TNF-Related Apoptosis Inducing Ligand (TRAIL) and its role in 
tumorigenesis  
TRAIL or Apo2 ligand (TRAIL/Apo2L/TNFSF10) is a cytokine of the TNF 
superfamily, whose members share a TNF structural motif – TNF Homology Domain 
(THD).  At present the family consists of 19 members that activate diverse cellular 
processes as proliferation, differentiation and apoptosis (Aggarwal, 2003). Their cognate 
receptors, TNF receptor (TNFR) superfamily, consists of 29 members and are distinguished 
by presence of cysteine bridges-containing pseudorepeats, also called cysteine rich domain 
(CRD) in their extracellular parts. A subgroup of the receptors within TNFR superfamily 
contains a death domain (DD) and can upon activation induce apoptosis of the receptor 
expressing cells (Aggarwal, 2003). 
TRAIL was discovered in 1995 by THD homology-based computer search in 
expressed a sequence tag (EST) library (Wiley et al., 1995). For its specific tumor 
cells-induced apoptosis, TRAIL received significant attention as potentially novel 
anti-tumor agent. In contrast to  other members of TNF family (e.g. TNF-α or FasL), 
systematic administration of the recombinant TRAIL did not lead to any toxic side effects 
neither in mice nor in primates (Lawrence et al., 2001). TRAIL is thus being a rare example 
of such molecules that can eliminate many transformed cells while sparing normal ones. 
Moreover, TRAIL can induce tumor cells apoptosis independently of their p53 status 
(Nagane et al., 2001) (tumors with mutated p53 are more difficult to eradicate using the 
conventional chemotherapy). This offers an attractive possibility of simultaneous 
administration of TRAIL and widely-used anti-cancer drugs or radiation treatment. 
Synergistic effects of TRAIL with etoposide, cisplatin, irinotecan oxaliplatin; protease 
inhibitors MG321 and bortezomib and γ-irradiation on enhancing tumor cells apoptosis 
have been documented in a number of reports (reviewed in (Duiker et al., 2006)) .  At the 
present are ongoing phase I/II clinical trials with both recombinant TRAIL (Genentech) 
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and with the agonist humanized anti-TRAIL-R1 and -R2 monoclonal antibodies (Human 
Genome Sciences) and the up to now results look very promising (Duiker et al., 2006).  
 
II.1.1 Structural and biochemical characterization of TRAIL 
Human gene for TRAIL, is localized at 3q26 of chromosome 3 and encodes a 281 
aa protein with predicted molecular weight 32509 Da (Wiley et al., 1995). TRAIL is a 
typical type II transmembrane protein, with one transmembrane hydrophobic region and 
absent signal sequence. Although TRAIL occurs mostly in membrane-bound form, it can 
be also proteolytically cleaved, albeit apoptosis-inducing activity of this soluble form is 
compromised (Mariani and Krammer, 1998). 
As other members of the TNF superfamily, TRAIL contains THD and forms 
“bell-shaped” trimers (fig. II. 1). Common features of THDs are a very similar tertiary fold 
and their ability to form trimeric proteins (Mariani and Krammer, 1998). Crystallographic 
studies revealed that each subunit contains a rigid frame of two anti-parallel beta sheets 
(beta sheet sandwich structure) and loops connecting individual sheets are highly 
disordered in the thinner part of the bell. TRAIL is unique within the TNF superfamily as it 
contains a 15 residue-long extension in one loop that spans the complete outer surface of 
the monomer (Cha et al., 2000). This elongated loop is suggested to enable specific 
recognition of TRAIL receptors (Cha et al., 2000). Another exceptional feature of the 
TRAIL is presence of zinc ion-binding site made of cysteine (Cys)-230 residues at the 
trimer interface, which is crucial for the maintenance of optimal biological activity 
(Hymowitz et al., 2000).  
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Figure II. 1: The structure of the TRAIL-DR5 complex. Left: trimer of TRAIL subunits (yellow, cyan, 
pink) and DR5 (blue, green, red); TRAIL trimer is enclosed in a transparent molecular envelope. Right: the 
complex viewed down the three fold axis; ad (Mongkolsapaya et al., 1999). 
 
II.1.2 TRAIL Receptors  
TRAIL interacts with five trimeric receptors, whose discovery opened yet not 
resolved discussion about a purpose of their multiplicity. Only two of the five TRAIL 
receptors, namely death receptor 4 (DR4/TRAIL-R1) and death receptor 5 (DR5/TRAIL-
R2) are capable of inducing cell death after TRAIL ligation. This is thanks to death 
domains (DD) in their intracellular portions. DD is a specific protein-interaction domain 
which serves as a binding site for essential pro-apoptotic adaptor proteins. DR5 and shares 
58 % homology with DR4 and both receptors are expressed in wide range of tissues and are 
strongly upregulated on activated lymphocytes (MacFarlane et al., 1997).  
As TRAIL signaling is proposed to play an important role in tumor 
immune surveillance, mutations in components of TRAIL signaling pathway can occur 
during tumorigenesis. Polymorphism in the ligand-binding domain of DR4 has been 
connected with a higher risk of bladder cancer, and other mutations within DR4 have been 
reported in cancer cells (Hazra et al., 2003). Conversely, the expression of non-mutant DR4 
in colon tumors was linked to favorable prognosis (Strater et al., 2002).  
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Existence of two death receptors for the same ligand could indicate their distinct 
role in regulation of tissue homeostasis or activation of secondary signaling pathways such 
as ERK, JNK, p38 MAP kinase and NF-κB ones (Malhi and Gores, 2006)1 (fig. II. 4.)  
In support of their distinct roles, Muehlenbeck et al. (2000) using DR5-specific 
TRAIL mutants showed that the JNK pathway is preferentially activated by DR5. Colon 
cancer cells preferentially use DR5-triggered apoptosis (Wang and El-Deiry, 2004) and in 
contrast, chronic B cell leukemia cells activate upon TRAIL ligation DR4-dependent 
apoptosis (MacFarlane et al., 1997). Also their transport to the cell surface is differently 
regulated as knockdown of signal recognition particle (SRP) protein SRP72 compromises 
only DR4 but DR5 cell surface localization (Ren et al., 2004). Increased DR5 expression 
could be characteristic for transformed cells as majority of normal cells express only low 
levels of DR5 at the cell surface (Wang and El-Deiry, 2004).  
Unlike death receptors, so-called decoy receptors upon ligation with TRAIL do not 
induce cell death. Decoy receptor 1 (DcR1/TRAIL-R3) lacks the cytoplasmic part and is 
attached to the membrane through a glycosylphosphatidylinositol (GPI) anchor. It is less 
widely expressed than other TRAIL receptors (Degli-Esposti et al., 1997). Decoy receptor 
2 (DcR2/TRAIL-R4) is relatively more expressed than TRAIL-R3 and has got a high 
degree of homology to the other TRAIL receptors. It has transmembrane region and a 
truncated death domain lacking two thirds of its regular length (Marsters et al., 1997).  The 
initial interpretation of their function was that they could serve as “decoys” competing with 
DR4/5 for binding to TRAIL. Nevertheless, this “decoy hypothesis” was challenged after 
experiments using monoclonal antibodies specific for each of the membrane-bound TRAIL 
receptors found no correlation between TRAIL resistance and decoy receptors expression.  
However, several new lines of evidence recently implied that forementioned receptors 
                                                          
1 Interestingly, the proteins that are required for apoptosis and NF-κB activation are recruited 
competitively (Jin and El-Deiry, 2006). In TRAIL-resistant tumor cells activation of these secondary 
signaling pathways (mainly NF-κB) enhances their proliferation potential. Thus, TRAIL binding can promote 
tumor growth and survival in such cells (Malhi and Gores, 2006).  
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actually act as effective DR antagonists at least in some tissues, thus the “decoy 
hypothesis” is not absolutely refuted (Merino et al., 2006). 
Third antagonistic TRAIL receptor is not membrane-bound but soluble 
osteoprotegerin (OPG). OPG is also high affinity decoy receptor for RANKL (receptor 
activator of NF-κB ligand). However, no functional relation between RANK-RANKL and 
TRAIL-TRAIL-R systems has been reported up to date (Vitovski et al., 2007).  
 
II.1.3 TRAIL-induced apoptosis 
II.1.3.1 Executive mechanisms of apoptosis 
Signaling pathways leading to apoptosis are usually divided according to their 
triggers, which are either extracellular or intracellular (Fig. 2). Extrinsic pathway is directly 
dependant on signals from environment e.g. death ligands recognized by death receptors  
(Hipfner and Cohen, 2004). The main activators of the intrinsic apoptotic signaling are 
reactive oxygen species (ROS), misfolded proteins or damaged DNA, viral infection, and 
oncogenes (Kowalik et al., 1995; Lowe et al., 1994). In case of TRAIL-induced apoptosis, 
extrinsic and intrinsic signaling pathways may be combined via complex interactions of the 
molecules they involve (Jin and El-Deiry, 2006). 
 
II.1.3.2 Caspases as apoptosis executioners 
Caspases are site-specific proteases, which cleave tetrapeptide recognition motif in 
the target protein after aspartate residue. Caspases are expressed as inactive zymogens and 
require proteolytic processing and dimerization for their full activation. Active caspases 
contain cysteine in their active center and form heterotetramer containing two large (20 
kDa) and two small (10 kDa) subunits (Cohen, 1997; Riedl and Shi, 2004). 
Caspases involved in apoptosis are split into two groups. Initiator or “priming” 
caspases are activated in specific multiprotein complexes after recruitment via their 
characteristic long N-terminal prodomains containing either the death effector domain 
(DED) (e.g., caspase-8/-10) or the caspase recruitment domain (CARD) (e.g., caspase 9). 
Upon activation, the initiator caspases cleave effector or “downstream” caspases (e.g., 
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caspase-3/-6/-7) or other proteins at their specific aspartate-containing sites. This 
processing and following conformational change-induced activation of downstream 
caspases then unlashes cleavage of wide spectrum of vital proteins as cytoskeletal 
components (actin, lamins), cell-cycle regulators, anti-apoptotic proteins, inhibitors of 
nucleases, components of DNA synthesis/repair machinery, kinases etc. (at present over 
one hundred caspase substrates are described) and subsequent dismantle of cell from within 
(Degterev et al., 2003).  
Since caspases function as apoptosis executors, they are potentially dangerous and 
must be tightly regulated to prevent undesirable cell death. Caspase activity is therefore in 
these processes as well as during apoptosis controlled by cellular inhibitors as caspase-8 
competitor FLIP or by inhibitors of apoptosis proteins (IAPs) (Riedl and Shi, 2004). 
 
II.1.3.3 Extrinsic pathway sequence in TRAIL-induced apoptosis 
II.1.3.3.1 Ligation of receptors – early events  
The main signaling TRAIL receptors are TRAIL-R1/DR4 and TRAIL-R2/DR5  
(Kimberley and Screaton, 2004) which represent a typical triggers of extrinsic apoptotic 
pathway. TRAIL death receptor signaling does not have to induce apoptosis by default, but 
under certain conditions when apoptosis is inhibited it also induces proliferation of the 
target cells (Malhi and Gores, 2006). Ligation of DR4 and DR5 by trimeric TRAIL leads to 
formation of intermediate activation complexes that in the apoptotic branch of their 
intracellular signaling contain the adapter protein FADD. FADD in addition to 
receptor-interacting DD also contains a death effector domain (DED), which serves for 
subsequent recruitment of procaspase-8 and/or -10 and assembly of Death-Inducing 
Signaling Complex (DISC). Proximity-activated processing of the initiator procaspases 
leads to their full activation and unlashing the downstream signaling that eventually 
activates the effector caspases and cell death (Cohen, 1997).  
TRAIL receptors may be a subject of regulation and therefore may also represent 
first source of TRAIL-resistance. Despite the infirmed decoy hypothesis, another way of 
apoptosis regulation by decoy receptors was suggested. Mérino et al. (2006) recently 
proposed a model, in which TRAIL-R3/DcR1 titrates TRAIL within lipid rafts, while 
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TRAIL-R4/DcR2 forms inactive trimers with DR5. Receptors-associated TRAIL resistance 
may be also important in tumorigenesis. In metastatic breast cancers, a missense mutation 
G-to-A at nucleotide 422 changing histidine for arginine at codon 141 (R141H) occurs in or 
near the ligand-binding domain of DR4 possibly affects receptor trimerisation or ligand 
binding. (Shin et al., 2001). 
 
II.1.3.3.2 Formation of DISC and downstream events 
Assembly of the DISC is an essential molecular event in the signaling pathway of 
TRAIL-induced apoptosis and downstream apoptotic signaling divides cells into two 
groups (Aggarwal, 2003). In type I cells, caspase-8 is activated at the DISC in quantities 
large enough to directly activate effector caspases as caspase-3. In type II cells, however, 
the amount of active caspase-8 produced at the DISC is smaller and insufficient for 
effective activation of the effector caspases. In these cells a mitochondrial amplification 
loop is required for full activation of caspases (described in details later). Differences 
between type I and type II cells can have important implications for cancer cell resistance 
mechanisms (Aggarwal, 2003).  
The fact that absence of either of DISC components was found in different types of 
tumor cells suggested that loss of functional DISC contributed to tumor development. Loss 
of caspase-8 expression has been demonstrated in malignant medulloblastomas, Ewing 
tumor, rhabdomyosarcomas, retinoblastomas and small cell lung carcinomas (Hopkins-
Donaldson et al., 2003; Zuzak et al., 2002). In this respect, inactivating caspase-8 gene 
mutations have also been described in some types of tumor cells such as colorectal 
carcinoma and squamous carcinoma cells (Mandruzzato et al., 1997).  
Competitive inhibitor of procaspase-8, FLICE-like inhibitory protein (FLIP) can, 
when overexpressed, protect cells from death receptor-induced apoptosis. Indeed FLIP 
overexpression was detected in colonic adenocarcinomas, hepatocellular carcinoma and 
melanoma (Ryu et al., 2001). Despite findings that overexpression of FLIP increase 
resistance to TRAIL, physiological function of FLIP remains unclear. It was recently 
suggested that FLIP may help cancer cells to acquire some degree of immune privilege 
(French and Tschopp, 1999).   
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II.1.3.4 Role of mitochondria and TRAIL-induced intrinsic apoptotic loop 
Mitochondria play crucial role in apoptosis, standing on the crossroad of multiple 
apoptotic signaling pathways that serve as an integrator of largely intrinsic but also some 
extrinsic signals (fig. II. 3) (Joza et al., 2002).  
In mitochondria reside molecules that can promote cell death in either caspase-
dependent (cytochrome c) or caspase-independent manner (apoptosis-inducing factor 
(AIF)) (Ravagnan et al., 2002). Cytochrome c (cyt c) is soluble 12kDa protein located in 
intermembrane space of mitochondria serving as a part of electron transport chain. When 
released, it forms heptameric structure together with caspase-9, dATP and Apoptotic 
protease activation factor-1 (Apaf-1), so called apoptosome (Adrain and Martin, 2001). In 
this multiprotein complex, caspase-9 undergoes activation by proteolytic cleavage and 
subsequently activates processing of effector caspases and caspase-dependent apoptosis. In 
mitochondria reside also other pro-apoptotic molecules as IAP inhibitors Smac/DIABLO 
and HtrA2/Omi or nucleases AIF or endonuclease G that can apparently promote PCD 
without activation of downstream caspases (Ravagnan et al., 2002).  
The principal regulators and promoters of apoptosis connected with mitochondria 
are proteins of the Bcl-2 (discovered in B-cell lymphoma) family (Cory et al., 2003). This 
relatively large group of signaling molecules consists of both pro- and anti-apoptotic 
proteins, whose common feature is presence of one to four so-called Bcl-2 homology (BH) 
domains (fig. II. 2). 
Bax, Bak and Bok are members of the Bax-like subfamily of pro-apoptotic proteins 
and contain BH1, 2 and 3 domains. In inactive form Bax resides in cytosol but Bak is 
already located at the mitochondria and their localization/activity dramatically changes 
after an apoptotic stimulus. Bax moves to mitochondria where it similarly as Bak 
undergoes structural changes and via multimerization Bax/Bak produce large pores in the 
outer mitochondrial membrane, leading to mitochondrial outer membrane permeabilization 
(MOMP) and release of the pro-apoptotic proteins as cytochrome c or AIF from the 
intermembrane space. In contrast to Bax proteins most of the anti-apoptotic Bcl-2 proteins 
as Bcl-2, Bcl-xL, Mcl-1, Bcl-W, Bcl-G contain one additional BH4 domain. Major function 
 21
of these anti-apoptotic proteins is dimerization-mediated inhibition of the pro-apoptotic, 
pore-forming activities of Bax proteins. Bcl-xL moreover negatively regulates Apaf-1 and 
apoptosome formation. Higher Bcl-2 and Bcl-xL level are also associated with tumor 
resistance to chemotherapy (Danial and Korsmeyer, 2004).  
Finally, BH3-only proteins represent the third subgroup of the Bcl-2 family. These 
proteins contain only BH3 domain and function as sensors or sentinels of cellular stress 
(Huang and Strasser, 2000). In mammalian cells apoptotic signaling activated by BH3-only 
proteins is complex and at the present there is known over ten BH3-only proteins (e.g., 
Bim, Bid, Bad, Bik, Noxa, Puma, Hrk/DP5, Bmf). Individual BH3-only proteins are 
responsible for apoptotic responses to various kinds of cellular stress and are activated 
through posttranslational modification (Bim, Bad, Bmf), or de-novo transcription (Puma, 
Noxa, Hrk). Activated BH3-only sentinels then translocate to mitochondria where they 
bind to and inactivate anti-apoptotic, Bax-inhibitory function of the Bcl-2 proteins (Huang 
and Strasser, 2000). 
 
 
Figure II. 2: Three subfamilies of Bcl-2 related proteins; ad (Henson et al., 2003) 
Mitochondrial level of TRAIL-induced apoptosis propagation is mainly important 
regarding type II cells. As mentioned above these cells need mitochondrial amplification 
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loop for successful propagation of cell death (Danial and Korsmeyer, 2004). This is 
achieved by cleavage of a Bcl-2 family member Bid. When cleaved by caspase-8, emergent 
tBid (truncated Bid) translocates to the mitochondria, where it together with Bax/Bak 
participates in activation of the mitochondrial apoptotic signaling Bcl-2 protein family and 
mitochondrial inhibitor of IAPs named Smac/DIABLO play the main roles at this level of 
regulation (fig. II. 3).  
Retroviral expression of Bcl-xL in originally TRAIL-sensitive cell line Colo357 
rendered these cells TRAIL-resistant (Strater et al., 2002). Interestingly 
Bcl-xL-overexpressing Colo357 cells had the same degree of caspase-8 cleavage as the 
original TRAIL-sensitive cells suggesting that caspase-8 activation was upstream of the 
mitochondrial pathway. In another study overexpression of Bcl-2 conferred protection 
against TRAIL in neuroblastoma and glioma cell lines (Fulda et al., 2002). In this case 
TRAIL-induced caspase-8 cleavage was reduced suggesting that caspase-8 was activated 
both upstream and downstream of mitochondria in these cells. As apoptosis induced by 
chemotherapy acts mainly through the mitochondrial pathway (Danial and Korsmeyer, 
2004), downregulation of. Bcl-2 and Bcl-xL might restore sensitivity not only to 
chemotherapy but also to TRAIL in these types of cancer.   
 
 
Figure II. 3: Overview of apoptotic signaling in mammalian cell; The explanation of basic apoptotic 
pathways is given in text; ad (Joza et al., 2002) 
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Smac/DIABLO is apoptosis regulator that is normally resident in mitochondria. 
After mitochondrial apoptotic pathway activation, it is released to the cytosol where it 
binds IAPs and thus hinders their inhibitory function (Joza et al., 2002). Blocking the 
release of Smac/DIABLO has been associated with TRAIL resistance in some, but not all, 
melanoma cell lines (Joza et al., 2002). TRAIL-resistant type II cancer cell lines compared 
with TRAIL-sensitive type II cell lines show reduced release of Smac/DIABLO and 
overexpression of Smac/DIABLO by transfection sensitized the resistant TRAIL-resistant 
type II cells to TRAIL (Zhang and Fang, 2005). Therefore Smac/DIABLO seems to be one 
of the major determinants of TRAIL sensitivity in these cells. 
 
Figure II. 4: TRAIL receptor signaling. Ligation of TRAIL receptors (DR4 or DR5) usually triggers 
apoptotic pathway (trapezoid). Alternatively it can also lead to activation of NF-κB or c-Jun, which is both 
connected with anti-apoptotic effect via upregulation of pro-survival genes. ad (Aggarwal, 2003) 
 
II.1.4 Physiological function of TRAIL 
Physiological in vivo function of TRAIL-induced signaling was intensively studied 
in murine models. However, instead of two signaling  human TRAIL receptors DR4 and 
DR5, mice have only one named mDR5 (murine death receptor 5), which is similarly 
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homologous to the human DR4 and DR5 (Wu et al., 1999). Thus the biological function of 
TRAIL signaling in mice does not have to fully reconcile its function in humans.  
TRAIL-/- mice were viable, fertile and without any developmental defects and their 
examinations did not point to any crucial role for TRAIL in embryonic development 
(Sedger et al., 2002). However, their enlarged thymus raised former suspicion that TRAIL 
and its receptors have a role in the immune system (Sedger et al., 2002). Possibility that 
TRAIL has a role in immune surveillance of cancer has been extensively studied after 
Sedger et al. (2002) showed that a syngenic transplant of a B cell lymphoma grows much 
slower in TRAIL+/+ mice and also forms less liver metastases than TRAIL-deficient mice. 
Later this anti-metastatic effect was assigned to NK cells and NKT cells that reduced the 
number of liver metastases in a TRAIL-dependent manner. TRAIL-/- and TRAIL-R-/- mice 
displayed higher frequency in developing spontaneous lymphomas at higher age (more than 
500 days). Also tumors induced with the carcinogen methyocholantrene developed more 
often in TRAIL-/- mice (Cretney et al., 2002). However,  loss of TRAIL-R did not 
accelerate incidence of lymphomas in p53-deficient mice (Yue et al., 2005). Hence, the 
TRAIL/TRAIL-R system at least in mice does not overtake of a tumor suppressor but 
apparently serves as one of the “weapons” of the immune surveillance that could be 
important for anti-metastatic defense. Importantly, as mentioned in the beginning of this 
chapter, TRAIL system could play much more important role in anti-tumor protection in 
long-lived mammals as humans. 
In spite of mTRAIL mRNA expression in majority of tissues, there is no detectable 
mTRAIL on the surface of freshly isolated T cells, natural killer (NK) cells, NKT cells, 
monocytes, dendritic cells (DC) or B cells (Kayagaki et al., 1999). Nevertheless many 
innate immune cells as NK cells express mTRAIL after stimulation with interferon (IFN)-γ, 
IFN-α, IFN-β, interleukin (Il)-2, Il-15 or lipopolysaccharide (LPS) (Johnsen et al., 1999). 
Subset of hepatic NK cells constitutively expresses TRAIL in an autocrine IFN-γ-
dependent manner (Zamai et al., 1998). Immature NK cells also express TRAIL and lose its 
expression after their maturation into granulated NK cells , whereas a small NK cells group 
does not undergo this maturation (Zamai et al., 1998). The persistent TRAIL-positive NK 
cells subset could then possibly serve for elimination of immature DCs, which are sensitive 
for TRAIL-induced apoptosis (Hayakawa et al., 2004).   
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TRAIL cell surface expression is increased on stimulated T cells. Anti-CD3 
mediated activation of TH1 but not TH2 leads to upregulation of TRAIL and simultaneous 
increase of anti-TRAIL resistance in respective cells (Zhang et al., 2003). TRAIL signaling 
could also play a role in development of autoimmunity. Most of murine model-based 
studies describe a suppressive function of TRAIL on progress of artificially induced 
autoimmune diseases such as encephalomyelitis, diabetes or rheumatoid arthritis (Mi et al., 
2003). Nonetheless, other autoimmune diseases as neuroinflammation may be accelerated 
by TRAIL (Aktas et al., 2005). 
  
II.2 Cellular hierarchy 
II.2.1 Stem cells  
Stem cells are defined by their functional ability to (i) generate more stem cells and 
(ii) generate cells whose descendants differentiate into various cell types (Morrison and 
Kimble, 2006). The definition readily fits a newly fertilized egg, however even many adult 
organs contain stem cells (adult/tissue stem cells) that posses this unique capability called 
self-renewal (Qu and Shi, 2009).  
Self-renewal is thought to exist in two forms. According to Yatabe (2001) about 
95 % of the time a stem cell divides asymmetrically to leave one stem cell and one 
daughter cell that differentiates (=asymmetric self renewal). Sometimes (about 2,5 % of 
divisions) a stem cell produces one stem cell and one committed cell (=symmetric self-
renewal); and the remaining 2,5 % of cases the stem cell becomes extinct as it produces 
two committed cells. Interestingly, it was shown that some cells seem to switch between 
both types of cell division according to needs of organism. This phenomenon was described 
e.g., in embryonic development or after injuries when stem cell pool expansion was 
required (reviewed in (Morrison and Kimble, 2006)). Hence, tissue stem cells apparently sit 
at the apex of tissue hierarchy, and are essential for maintenance of tissue homeostasis. 
Unfortunately, in contrast to embryonic stem cells the origin of adult stem cells is poorly 
understood. We also lack detailed information on the molecular programs and signaling 
governing these processes. Nonetheless, it is widely recognized that interaction of cells 
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with so called stem-cell “niche” is strongly involved in maintenance of stemness, and thus 
regulation of cell division and differentiation (Tulina and Matunis, 2001).    
      
 
II.2.2 Tumorigenesis as a stem cell associated process 
In the classical model of tumorigenesis by Nowell (1976), malignancy is viewed as 
a clonally-derived cell population, which acquires new potentially advantageous mutations 
that give rise to new more rapidly proliferating clones. Cell type which is most suitable for 
unlimited proliferation in the given environment then out-competes the less adapted clones 
in a process of clonal selection and becomes temporarily predominant (Nowell, 1976). This 
idea was based on genetic analysis of tumors at different stages of progression combined 
with the examination of subsets of clones within the tumors (Merlo et al., 2006). The 
source of apparent heterogeneity of cells within most tumors has been implicitly assigned 
to high instability of their genomes and micro-environmental influence.  
However, novel insights in cancer and stem cell research, namely the recent 
discovery of stem cells in various adult organs and demonstration of their striking 
similarity to tumor cells, led to a renaissance of an alternative model that has been existing 
for decades. In this so called cancer stem cell (CSC) hypothesis, heterogeneity of tumor cell 
populations is explained by the possibility that tumor, analogically to a healthy tissue, is 
hierarchically organized (Hope et al., 2004). Cancer stem cells are then hypothesized to be 
a small subpopulation of cells sitting atop tumor hierarchy that are able to self-renew and 
undergo differentiation to generate various cell phenotypes observed in tumors. 
Importantly, according to CSC hypothesis, CSCs are the only cells of tumor that posses a 
capacity of unlimited growth, and are responsible for its progression, drug resistance, and 
recurrence; thus they present an ideal therapeutic target for a successful eradication of 
tumors (Ichim and Wells, 2006). Descendants of the CSCs, that have lost self-renewal 
capacity, can proliferate for a finite number of cell divisions before they ultimately 
differentiate to give rise to a much larger population of cells that can no longer proliferate.  
Early observations suggesting that majority of cancer cells cannot proliferate 
continuously come from Mendelsohn (1960), who noted that only a portion of mammary 
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adenocarcinoma cells referred to as “growth fraction” incorporated 3H-thymidine. 
However, pivotal experimental support for CSC theory came at first from acute myeloid 
leukemia in which a rare subset comprising 0,01-1% of total population could induce 
leukemia when transplanted to immunocompromised mice (Bonnet and Dick, 1997). 
Subsequently, evidence supporting the existence of CSCs was extended to solid tumors 
including melanoma, liver, lung, breast, prostate, brain, head and neck, pancreatic, 
mesenchymal and colon cancer (reviewed in (Visvader and Lindeman, 2008)). 
Unfortunately, limitations of xenograft assays used in these experiments confer to the fact 
that the proof of CSCs, at least for solid tumors, is highly controversial so far.    
 
II.2.2.1 Origin of CSCs 
The origin of CSC is still a subject of ongoing discussion2. Several interpretations 
of CSC hypothesis have emerged regarding this issue and some of them are not necessarily 
mutually exclusive. First, a tissue specific stem cell could be expected to be the target of 
transformation since the mitotically-active lifespan of differentiating cells seems too short 
for acquiring the necessary number of mutations (Jackson and Loeb, 1998). This opinion is 
supported by the observations that common signaling pathways regulate self-renewal in 
both normal and putative cancer stem cells (Al-Hajj and Clarke, 2004). Data obtained from 
analysis of promoter methylation showed that epigenetic profile of colorectal cancer 
samples, is similar to that of embryonic stem cells (Widschwendter et al., 2007). Further, 
Blair (1998) and others have shown that CSCs may share with their normal counterparts 
some immunophenotypic antigens.  
                                                          
2Since the CSC might be misleading denomination for these cells of uncertain origin and relation to normal 
stem cells, some authors proposed/preferentially use the term “tumor-initiating cell” (TIC) for cell capable of 
tumor re-initiation after its transplantation in immunocompromised mice (Neuzil et al., 2007). For purpose of 
this thesis, I use CSC nomenclature, so far more prevailing in literature. Moreover, the term TIC may evoke a 
perception that it refers to the cell from which the (original/primary) tumor derived in the first place. This is 
likely not the case since there is a clear evidence that the CSC or tumor initiating cell population can undergo 
changes as the disease progresses (Clarke, 2004).    
 
 28
Alternatively, CSCs may be neo-stem cells; that is, they may originate in a 
differentiating cell that has re-acquired through carcinogenesis the capacity for self-
renewal. The latter possibility requires that acquisition of self-renewal occurs as a very 
early event in carcinogenesis, otherwise nascent cancer clones would be lost due to clonal 
extinction. Evidence for such reversal comes from experiments with MOZ-TIF2, MLL-
ENL fusion proteins, which are able to restore self-renewal in myeloid progenitors (Huntly 
et al., 2004).  
 
II.2.2.2 Markers of CSCs 
Number of ways has been proved effective for the isolation of subsets enriched for 
CSCs. Especially various membrane proteins have been suggested as markers of CSC 
populations depending upon tumor type and tissue of which the tumor originates. As hinted 
above, markers specific for normal stem cells of a given organ may be useful for CSC 
identification in respective tumors. Clarke et al., (2003) was first to indentify a cellular 
population displaying CSC-properties in a solid malignancy. Only a subset of breast tumor 
cells positive for CD44 and negative for CD24 (CD44+ CD24-/low) were able to form a 
new tumor when injected into mammary fat-pad of immunodeficient mice. The expression 
profile of CD44+ CD24- CSCs was likewise shown to be more similar to the normal breast 
epithelial stem cells (Al-Hajj et al., 2003). Similarly other surface antigens e.g. efflux 
transporters ABCB5, ABCG2 and those of yet obscure functions such as CD34, 
CD90/Thy1, CD133 have been used as CSC markers i.a. in melanoma, tumors of breast, 
lungs, liver and brain respectively (reviewed in (Visvader and Lindeman, 2008)). 
Expression of these and many other putative CSC markers is not absolutely tumor-
exclusive and it is rather their combinations that are specific for particular tumor type. 
Moreover, CSC phenotype may not necessarily be uniform between cancer subtypes and 
one marker may be typical for several different tumors.  
     
II.2.2.2.1 CD133/Prominin-1  
For instance, apart from glioblastoma, CD133 has been reported as a CSC marker in 
medulloblastoma, pancreas, lung and colon cancers. In some other tumors, combination of 
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CD133 with one or more markers is used. In prostate cancer, subset of 
CD44+/α2β1high/CD133+ cells were shown to possess a capacity to self-renew and derive 
aberrantly differentiated cells that form the bulk of the tumor.  
CD133 or human Prominin-1 is a pentaspan transmembrane glycoprotein of 865 aa 
and molecular weight 120 kDa, encoded by single copy gene on chromosome 4 (4p15.33). 
The CD133 molecule consists of N-terminal extracellular domain followed by 5 
transmembrane domains and cytoplasmic C-terminal domain. The transmembrane domains 
are joined by two short intracellular loops of 30 aa each and two big extracellular loops of 
255 aa and 290 aa respectively. Originally, CD133 was discovered as the target of 
monoclonal antibody (mAb), AC133, which was generated to bind CD34+ population of 
hematopoietic stem cells (Yin et al., 1997). Subsequently, it has been recognized as a 
suitable marker for stem cells of various origin e.g. fetal neural stem cells or renal, corneal 
and prostate tissue specific stem cells.  It was later suggested, that not CD133 itself but 
rather its certain glycosylated epitopes, such as the one recognized by AC133, should be 
considered as “stemness” markers3. This was based on several discrepancies in 
identification of CSCs (Shmelkov et al., 2008). Several studies have demonstrated that 
expression of CD133 mRNA or protein is not restricted to stem cells and the AC133 
epitope can be downregulated independently from CD133 during differentiation (reviewed 
in (Bidlingmaier et al., 2008)). Regrettably, very little is known about the molecular nature 
of recognized epitopes and their glycosylation. In fact, the exact location of the modified 
amino acid residues on CD133 targeted by AC133 and other commercial mAbs has not 
been described. An additional complexity ensues from alternative splicing that yields two 
known isoforms named AC133/1 and AC133/2 (Bidlingmaier et al., 2008).  The shorter 
AC133/2 isoform, lacking 9 aa in the N-terminal portion, was shown be downregulated due 
to differentiation in basal epidermal stem cells. Thus, Yu (2002) concluded that AC133/2 
but not AC133/1 is a marker of stem cells.     
The biological function of CD133, its eventual ligands or intracellular interacting 
partners remain unclear. Whether and how CD133 per se, or its splicing and glycosylation 
forms contributes to the maintenance of primitive phenotype is questionable. However, its 
                                                          
3 In this review I follow the notation of CD133+/- cells as it is used in original literature, even in the cases 
where experiments were done with commercial antibodies.   
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prominent localization in apical membrane protrusions and cholesterol-rich rafts is 
indicative of possible function in cellular polarization and signaling. Biological 
significance of CD133 was stressed by loss-of-function experiments, since mutation or 
absence of prominin-1 led to serious retinal defects and complete loss of vision (Maw et al., 
2000). 
 
 
 
II.2.2.2.2 ATP-binding cassette transporters 
ATP-binding cassette (ABC) transporters constitute a family of five membrane 
proteins serving as efficient protection against DNA-damaging agents. These transporters 
are important for stem cells, due to role of stem cells in tissue regeneration, but are 
downregulated following differentiation. For example, ABCG2 (or breast cancer resistance 
protein 1 (BCRP1)), plays major role in drug resistance, exhibiting broad spectrum 
substrate specificity (Kusuhara and Sugiyama, 2007).  Similarly, in melanoma ABCB5+ 
cells posses greater tumorigenic capacity than ABCB5- cells and have significantly higher 
capacity for self-renewal and differentiation (Schatton et al., 2008).  
Identification of stem cells/CSC based on ABC transporters also involves subjecting 
of cells to DNA binding fluorescent dyes (e.g. Hoechst 33342) followed by FACS. This 
results in a distinct so called “side population” of cells marked by a low uptake of the dye 
(Zhou et al., 2001). 
 
II.2.2.2.3 Other putative CSC markers 
Besides membrane proteins, aldehyde dehydrogenase (ALDH) activity has been 
frequently used as a marker of both normal and cancer stem cells in many tumors and even 
cancer cell lines (Ginestier et al., 2007). Surprisingly, the ALDH1+ population in breast 
cancer shows only small overlap with the previously described CD44+CD24-/low 
phenotype (0,1-1,2%) (Al-Hajj et al., 2003). In this case, variation in marker expression 
could be attributable to culturing of cells before cell sorting rather than the use of fresh 
material; moreover phenotypic conjunction of CD44+CD24-/low and ALDH1+ yielded a 
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highly CSC-enriched population. Though, more careful examination will be surely needed 
to overcome present ambiguity of CSC markers, eventually, in order to design CSC-
specific cancer therapy. 
 
II.2.2.2.3.1 Sphere assay for identification of putative CSC    
Sphere assay is a method originally developed for identification of normal stem 
cells.  It was shown that normal adult stem cells form spheroid bodies when cultivated in 
non-adherent serum-free conditions and subsequently this setup was used for identification 
or enrichment of cancer stem cells (Galli et al., 2004). It remains however elusive, how and 
why are the spheres created. In addition, fact that both stem cells and progenitors may form 
spheres infirmed some previous inferences regarding stem cell-enrichment (Marshall et al., 
2007).   
 
II.2.2.3 Apoptosis and drug resistance of CSCs 
Resistance of putative CSCs is usually correlated to the fundamental properties they share 
with normal SCs. Besides ABC transporter-mediated drug efflux and radioresistance due to 
activation of DNA-damage response (Bao et al., 2006), some other mechanisms have been 
recently discovered. For example caspase promoter hypermethylation was previously been 
linked to TRAIL-resistance (Hopkins-Donaldson et al., 2003)and a very recent study by 
assigned the TRAIL-resistance of SC-like glioma cells to the same mechanism (Capper et 
al., 2009). In a study by Zobalova (2008) CD133 positive MCF7 cells were resistant to 
TRAIL due to upregulated FLIP, and its silencing by siRNA lead to their sensitization.   
 
II.2.2.4 CSC niche 
Analogically to the situation with normal stem cells, stromal-epithelial interactions 
have been shown to be crucial in survival and differentiation of cancer cells (Cunha and 
Hom, 1996). Fibroblasts are a major constituent of the stromal compartment. The extent to 
which fibroblasts can directly influence the phenotype of individual cancer cells is not yet 
known. However, an integration of several recent observations suggests enormous hidden 
potential of this issue. Not only various cancer-associated fibroblasts (CAFs) were 
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suggested to promote tumor invasion (Qian et al., 2003), growth (Olumi et al., 1999) and 
production of angiogenic factors (Koshida et al., 2006); in a recent study done by Smetana 
et al., (2007) various fibroblasts derived from skin tumors were shown to induce 
dedifferentiation of keratinocytes.  
CAFs were shown to secrete elevated levels of stromal cell-derived factor 1 (SDF-
1) which trough its receptor CXCR4 activates signaling pathways related to motility, 
chemotaxis, and adhesion (Orimo and Weinberg, 2006). Interestingly, CXCR4 is also 
upregulated in stem cells, enabling their remarkable homing ability important for growth 
and development (Natarajan et al., 2006). Also another factor potentially regulating 
self-renewal of cells, BMP antagonist GREMLIN1 was observed in tumor niche of Scc 
(Sneddon et al., 2006).   
 
Figure II. 5: Role of tumor niche in solid tumor patogenesis. Tumor niche is created by blood vessels and 
fibroblasts. Niche renders support to CSC compartment, possibly enhancing its self-renewal and 
drug-resistance. CSCs self-renew and simultaneously generate large pool of (pseudo-)differentiated non- 
CSC tumor cells. ad(Ailles and Weissman, 2007) 
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 III. Materials and Methods 
 
III.1 Cell culture 
III.1.1 Cell lines 
All cells used in this study were derived from human healthy or cancerous tissues. 
The cell lines and primary cells used during this study are listed in tab. III. 1. 
 
name type of cells, tissue of origin disease  stage  source
HCT 116 epithelial, colon epithelium colorectal carcinoma  n/a ATCC, USA
HT-29A3 secretory epithelial, colon epithelium colon adenocarcinoma  Dukes' type C Dr. E. Šloncová, IMG, ASCR
CX-1 secretory epithelial, experimental metastasis (nude mouse model) colon adenocarcinoma n/a DSMZ, Germany
RKO epithelial, colon epithelium colon carcinoma n/a ATCC, USA
LoVo epithelial, left supraclavicular region colorectal adenocarcinoma Dukes' type C ATCC, USA
Colo-206F epithelial, ascites fluid colon carcinoma n/a DSMZ, Germany
SW 620 secretory epithelial, lymph node colorectal adenocarcinoma Dukes' type C ATCC, USA
SW 480 secretory epithelial, colon epithelium colorectal adenocarcinoma Dukes' type B ATCC, USA
LS-174T secretory epithelial, colon epithelium colorectal adenocarcinoma Dukes' type B ATCC, USA
DLD-1 epithelial, colon epithelium colorectal carcinoma Dukes' type C ATCC, USA
DLD-1E8 epithelial, colon epithelium colorectal carcinoma Dukes' type C produced by lentiviral infection
BccF B3 fibroblasts, skin basal cell carcinoma n/a 
Bfh B4 fibroblasts, skin benign fibrous histiocytoma n/a 
SccF S4 fibroblasts, skin spinocellular carcinoma n/a 
HF fibroblasts, skin no diagnosed disease .
Prof. K. Smetana Jr., Charles 
University in Prague, 1st Faculty 
of Medicine, Institute of Anatomy 
Prague, CR 
 
Table III. 1:  Cell lines and their specifications 
For simplification following acronyms are used further in text: E8 for DLD-1E8; B3 for BccF B3; B4 for  
Bfh B4,  S4 for SccF S4. 
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III.1.2 Culture media 
III.1.2.1 Culture media for propagation of cells 
HCT 116 and LS 174 T cell lines were cultured in Iscove's Modified Dulbecco's 
Media (IMDM) supplemented with 10 % FBS (Hyclone), non-essential amino acids 
(Gibco) and antibiotics (50 000 IU/l penicillin; 0.1 g/l streptomycin; 0.08g/l gentamycin; 
all Sigma). 
Colo-206F, LoVo, SW 480 and SW 620 were cultured in RPMI supplemented with 
10 % FBS (Hyclone) and antibiotics. 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % FBS 
(Hyclone) and antibiotics was used to culture DLD-1, HT-29A3, CX-1, RKO cell lines and 
SccF S4, Bfh B4, BccF B3, and HF primary fibroblasts.  
DLD-1E8 cells were maintained in selection media to ensure maintenance of 
expression plasmids, i.e. DMEM with 10 % FBS (Hyclone) and standard antibiotics 
supplemented with 3 μg/ml puromycin (Sigma). All above mentioned media are further 
also referred to as “regular” or “recommended” media. 
 
III.1.2.2 Serum free medium for cultivation of spheroids (NS-Ac) 
For cultivation of colon carcinoma cell lines in serum-free conditions (or sphere 
assay - SA) NeuroCult® NS-A proliferation medium (StemCell Technologies) was used. 
This medium was mixed from its components prior to each cultivation experiment, since 
single components are declared unstable and therefore inconvenient for long term 
maintenance in unfrozen state. Serum-free medium containing supplementation was stored 
in a dark place, at 4 °C, and has never been in use for longer than 1 week. We designated 
this medium “NS-A complete” (NS-Ac) and it was prepared as follows: 
NS-A basal medium and NS-A proliferation supplement4 (both StemCell 
Technologies) were thawed overnight at 4° C and mixed in 9 : 1 ratio in amounts sufficient 
for the respective experiment. Stock solutions of Heparin, human epidermal growth factor 
                                                          
4Contents of the commercial proliferation supplement is not provided by manufacturer. We estimate its 
character from analogous mixture for amplification of tumoral stem cells patented in WIPO under notation 
WO 2006/030473 A1. 
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(EGF) and human basic fibroblast growth factor (bFGF) (all Sigma-Aldrich) were thawed 
just before  the media utilization and added media to reach final concentrations of 2 μg/ml 
heparin, 20 ng/ml EGF, 10 ng/ml bFGF.  
 
III.1.3 Propagation, freezing and thawing of cells 
All primary cells and cell lines were grown in Petri dishes, cell culture flasks or 
multiwell plates with standard tissue culture treated surface (TPP). Cultivation was carried 
out in incubators (Sanyo) at 37 °C, 5 % CO2 (standard cultivation conditions). All work was 
done using sterile equipment and standard tissue culture techniques. Cell cultures were 
regularly checked for the presence of mycoplasma.  
The proliferation intensity of each cell line was acquired by counting its doubling 
time. Fresh cells (not sooner then 2 days but maximum 1 week after thawing) were 
harvested, counted in hemocytometer, diluted in fresh media to uniform low concentration 
of 30000 cells/ml and seeded in 6-well cell culture plates. Cells were incubated in standard 
conditions (as described previously) for 48 hours, then harvested and counted. The 
doubling time T is then calculated as follows: T = t * ln(2) / ln(c2/c1) where t is time of 
incubation, c2 is final and c1 initial concentration of cells. 
In case of primary fibroblasts, record of passages and population doublings was 
kept, and cells were not used when suspected of nearing senescence.     
Freezing of cells was performed in regular culture media with 20 % FBS and 10 % 
dimethylsulphoxide (DMSO) (Sigma-Aldrich). Cells in cryotubes (Nunc) were stored in 
freezing containers (Nalgene) at – 80 °C overnight and subsequently moved to liquid 
nitrogen (- 196 °C). 
Thawing cells was done rapidly in liquid bath (37 °C). Cells were diluted into 
medium, spun down, and then resuspended in warm regular medium. Viability of cells was 
assesed by trypan blue staining and was mostly between 65-95 %. 
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III.1.3.1 Cultivation of cells in serum-free conditions 
Before seeding in serum-free medium, cells were harvested, counted, centrifuged at 
250g, 4 °C, 5 minutes, (centrifuge 5810 Eppendorf, Germany), washed with PBS to remove 
residual serum and again centrifuged. Cells were resuspended in NS-Ac and seeded in 
clonal densities to either tissue culture treated (TTP) or non-treated (Nunc) multiwell plates.   
 
III.1.3.1.1 Subculturing spheroids  
For subculturing spheroids we used protocol for subculturing human neurospheres 
available at http://www.stemcell.com/technical/28724_Neurocult%20Human.pdf . For poor 
performance with plain trituration we extended the procedure for trypsinization step. 
Briefly: cells were spun in u-bottom multiwell plates or microtubes and supernatant was 
discarded. Cells were treated with trypsin-EDTA solution (Sigma-Aldrich), 10 minutes, at 
37 °C and repeatedly triturated trough pipette tips (circa 100x) until the single cell 
suspension was reached. Trypsinization was terminated by adding stechiometraical amount 
of soybean trypsin inhibitor (Sigma-Aldrich) to the suspension. Suspension was spun and 
washed twice with PBS. Cells were counted and resuspended in fresh NS-Ac medium. 
Importantly, during comparative experiments all cells were subcultured accordning to this 
protocol, including the non-spheroid cell lines and cells in regular media were treated 
analogically. Identical steps were also used for harvesting of cells prior to processing for 
analysis on flow cytometry.  
For minimizing exposure of cells to such burdening manipulation, experiments were 
designed to evade repeated subculturing. Cells were plated in low densities regarding their 
proliferation rates to obtain approximately equal cell counts in all tested cell lines at the 
time of processing. 
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 III.2 Treatment of cells with TRAIL 
For induction of apoptosis, recombinant TRAIL Killer (Apronex) was diluted to 
appropriate concentration in prewarmed respective media and added to incubation with 
cells for required time. Stock of TRAIL was divided into small aliquots (before storing at 
-80 °C) to prevent repeated freeze-thaw cycles, thus maintain constant quality of used 
reagent.  
 
III.3 Flow cytometry 
III.3.1 Measuring of apoptosis 
We used two flow cytometric approaches for measuring of apoptosis utilizing 
intracellular and superficial staining of apoptotic cells.  
 
III.3.1.1 Annexin V FITC staining  
This procedure is based on loss of membrane phospholipid assymetry and exposure 
of phosphatidylserine (PS) in apoptotic cells. Cells are not fixed for this type of staining. 
Cells were harvested according to procedures described above and maintained in 
microtubes on ice. Cells were washed twice with ice cold PBS then resuspended in ice cold 
annexin V binding buffer (ABB) 1x (Apronex) and incubated 10 minutes on ice. Cells were 
spun, transferred in ice cold ABB 1x with annexin V FITC (Apronex) diluted to final 
concentration 0,5 μg/ml and incubated in dark place on ice for 30min. Cells were spun, 
washed with ice cold ABB 1x and resuspended in ABB 1x with propidium iodide (PI) 
(Sigma-Aldrich) diluted to final concentration 20 μg/ml. Samples were stored in dark until 
analysis by flow cytometry. 
Where not explicitly stressed, all washing (and transfering) steps were followed 
(and preceded) with centrifugation at 250 g, 4 °C, 5 minutes. 
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III.3.1.2 M30 FITC staining  
This procedure is based on detection of caspase-cleaved cytokeratin-18 in apoptotic 
cells. Cells are fixed for this type of staining. 
Cells were harvested according to procedures described above and maintained in 
microtubes on ice. Cells were washed twice with ice cold PBS then resuspended in ice cold 
methanol and fixed for 30 minutes in freezer at -20 °C. Cells were washed twice with PBS 
and resuspended in incubation buffer (PBS + 1% BSA) with M30 FITC conjugate (Roche) 
diluted to final concentration 0,5 μg/ml. After 30-min incubation in dark place at room 
temperature cells were washed twice with PBS and resusspended in PBS. Samples were 
stored in dark until analysis by flow cytometry. 
Where not stressed, all washing (and transfering) steps were followed (and 
preceded) with centrifugation at 250 g, 4 °C, 5 minutes. 
 
III.3.2 Profiling of surface proteins    
Cells were stained with directly conjugated antibodies or sequentially, with primary 
then secondary antibody in appropriate combiantions. Monoclonal antibodies used for 
analyses of death receptors and CSC markers are listed. Dead cells were excluded from 
analysis by addition of Hoechst 33258 (Sigma-Aldrich). 
 
target mAB host / isotype Manufacturer
DR4 MAb to TRAIL-R1 clone HS1010 mouse / IgG1 ALEXIS Biochemicals
DR5 MAb to TRAIL-R2 clone HS201 mouse / IgG1 ALEXIS Biochemicals
Fas (CD95) clone DX2 mouse / IgG1 R&D Systems
TNFR I clone 4.12 mouse / IgG2a Invitrogen
CD133/1 clone AC133  PE conjugate mouse / IgG1 Miltenyi Biotec
CD133/2 clone 293C3  PE conjugate mouse / IgG2b Miltenyi Biotec
ABCG2 clone 5D3 mouse / IgG2b R&D Systems
mouse IgG 115-115-164  PE conjugate goat / whole IgG Jackson Immunoresearch  
Table III. 2:  List of used antibodies 
 
Surface antigen staining protocol (sequential staining):  
Cells were harvested, centrifuged, washed with cold PBS resuspended in incubation 
buffer (PBS + 0,2 % gelatine (Sigma-Aldrich) and 0,1 % sodium azide (Sigma-Aldrich)) 
and maintained on ice. For blocking of eventual Fc-receptors normal human AB serum 
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(ExBio)  was added to incubation for 10 minutes, then the cells were spun, washed with 
cold PBS and resuspended in incubation buffer with diluted primary antibody (1 μg/ml). 
Cells were incubated with primary antibody 30 minutes on ice, then spun, washed twice 
with cold PBS and resuspended in incubation buffer with PE-labeled secondary antibody 
(1 μg/ml), stored in dark place on ice and incubated for 45 minutes. Cells were spun, 
washed twice with cold PBS and resuspended in PBS with Hoechst33258 vital dye  
(Sigma-Aldrich) (5 μg/ml).  Samples were stored in dark until analysis by flow cytometry.  
Where not stressed, all washing (and transfering) steps were followed (and 
preceded) with centrifugation at 250 g, 4 °C, 5 minutes.  
Direct staining (with AC133-PE and 293C3-PE conjugates) was performed 
analogically with omitting the first staining step.  
 
III.3.3 Cytometer setup 
 For all flow cytometric analyses, LSRII instrument (BD Bioscience, USA) was used. 
Samples were prepared in u-bottomed 96-well plates and loaded with HTS peripheral 
device of the cytometer. 
 Gating of vital i.e. non-necrotic population was enabled by co-staining with vital 
dyes (PI in annexin- FITC apoptosis assays, Hoechst 33258 (Sigma-Aldrich) in PE 
staining). Examples of gating are given in respective figures in results chapter.  
 
III.4 Caspase 3/7 glo assay 
Caspase 3/7 glo luminiscence assay (Promega) was performed as alternative method 
for assessing apoptosis. Since this assay measures the activity of enzymes in cellular 
lyzates and is purely quantitative, cells were carefully counted for every caspase 3/7 assay 
experiment. Cells must be plated on non-transparent white background for this assay; 
therefore duplicate with ordinary transparent plate was always simultaneously created to 
visually control the cell counts.  
Procedure was done according to manufacturer’s protocol, which is available at: 
http://www.promega.com/tbs/tb323/tb323.pdf   
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Luminescence was measured in duplicates on Luminoskan Ascent instrument 
(Thermo Scientific, USA) and background values of media were subtracted.    
 
III.5 Co-cultures with stromal fibroblasts 
 Two approaches were used in co-cultures of colon carcinoma cells with fibroblasts 
(co-cultures with conditioned media, and direct co-cultures). In case of direct co-cultures, 
subsequent flow-cytometry required to distinguish the cells with fluorescent labels. 
 
III.5.1 Preparation and application of fibroblast-conditioned media 
We used all four fibroblast types (tab. III. 1) for conditioning media for cultivation 
of colon cancer cell lines. Briefly: fibroblasts were grown to confluence. Their partially 
exhausted medium was replaced with fresh regular DMEM. DMEM was harvested after 
one day and added to colon cancer cells in 1:1 ratio with their respective fresh medium.    
 
III.5.2 Direct co-cultivation of colon cancer cells with fibroblasts 
III.5.2.1 Labeling of cells with CellTracker Red (CMTPX) 
CMTPX dye (Invitrogen) was used for staining of fibroblasts according to 
instructions of manufacturer. Briefly: the working solution of CMTPX was prepared by 
dissolving lyophillizated product in DMSO to concentration 10 mM and subsequently 
adjusting to final concentration 1 μM by dissolving initial stock in serum-free DMEM. 
Cells were grown in a multiwell plate to confluence. Medium was removed from the plate 
and prewarmed CMTPX working solution was added to the cells. Cells were incubated for 
30 minutes under standard conditions, then working dye solution was replaced with regular 
DMEM with 10 % FBS and incubated for another 30 minutes. During this time, according 
to manufacturer’s claims, the dye underwent chemical change (reduction) that prevents it 
from escaping intracellular compartment. Redundant dye or dye that failed to undergo 
reduction stayed in the supernatant. Medium was replaced again with the fresh prewarmed 
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regular DMEM with 10 % FBS. Since then, cells were cultured normally and were 
prepared for co-culture. 
 
III.5.2.2 Labeling of cells with RFP 
For labeling of cells with RFP we employed lentiviral infection approach. We 
generated stable trasfectants of colon carcinoma cell lines expressing RFP.   
 
III.5.2.2.1 Lentivirus production 
This work was kindly done by Dr. Anděra and Dr. Koc according to following 
protocol: http://mellgenlabs.com/Documents/ezlentifect_protocol.htm  RFP expressing 
lentivirus vector was used (Hebrew University of Israel). 
 
III.5.2.2.2 Infection of target cells 
Cells were grown in 24-well plate to 60% cell confluency. For one well 15 µl of 
concentrated virus supernatant was dropped into 0,5 ml of medium and incubated for 24h 
After that cells were washed 2 times the with PBS and let in the fresh medium with 
selective antibiotics (2 µg puromycin per ml of medium) for 24 h. Next day the medium 
was replaced and stronger doses of selective antibiotics added (3 µg puromycin per ml of 
medium). 
 
III.5.2.2.3 Selection of RFP- expressing clones 
RFP-expressing mixed cultures were diluted to very low clonal densities 
(approx.10 cells/ml) in regular media with puromycin (3 µg/ml) and seeded on 10cm Petri 
dishes. After 14 days of cultivation in standard conditions, individual colonies with the 
brightest expression of fluorescent protein were picked  in sterile conditions under 
fluorescence macroscope Z16 APO A (Leica, Germany) and placed in wells of 96-well 
plate with regular media and puromycin (3 µg/ml). Cells were subsequently expanded by 
regular cultivation in the continuous selection conditions to obtain sufficient amounts of 
 42
cells for cryopreservation in liquid nitrogen. Before freezing, cells which retained 
expression of fluorescent protein were characterized for their sensitivity to TRAIL-induced 
apoptosis (fig. IV. 10 a)).    
 
III.5.2.3 Seeding of cells for direct co-cultivation  
For all co-cultivation experiments, fibroblasts were seeded first to create a confluent 
feeder layer on the bottom of the plastic wells. Colon cancer cells (DLD-1E8, DLD-1, 
HCT 116) were diluted in regular media and seeded in low densities into plates with 
fibroblast feeders (fig. IV. 10 b)) Dilution of cells was calculated for cells according to 
their proliferation rates to obtain near sub-confluence before processing for analysis. For 
recording cellular morphology and expression of fluorescent protein, we used solely 
inverted fluorescence microscope DM 6000B with integrated camera (Leica, Germany). 
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 IV. Results 
  
IV.1 Initial characterization of used colon carcinoma cell lines 
Colorectal carcinomas represent one of most often diagnosed and deadly cancers in 
the population of mainly Western countries and were also reported to comply (at least in 
some reports) with the cancer stem cells (CSC) model of tumorigenesis(Ricci-Vitiani et al., 
2007). Therefore we in our experiments related to cancer stem cells rather intentionally 
focused on the analysis of colorectal cell lines, and in this study we used ten colon 
carcinoma cell lines of distinct origin and phenotypes. We started the experiments 
assessing basic properties of the cells including their doubling times, morphology and 
sensitivity to apoptosis induced by TRAIL. The analysis of the cell surface expression of 
death receptors and CSC markers was part of later experiments addressing phenotype of 
colon carcinoma cells depending on various cultivation conditions.   
 
IV.1.1 Morphology of colon cancer cells 
With a single exception of Colo-206F, all cell lines grew adherently in standard 
cultivation conditions and showed mostly uniform flat (HCT 116) to spindle-like (SW 480) 
morphology (fig. IV. 1a), b)). Colo-206F grew semi-adherently with a large number of 
floating or weakly adherent cells (fig. IV. 1c)), and this growth mode was not associated 
with a reduced viability. 
When grown adherently, HT-29A3 cell line slightly tended to aggregate and form 
irregularly shaped cloudlets even low cell density, whereas other colon carcinoma cells 
formed multiple layers with dome detached cells only at higher densities (fig. IV. 1d))..    
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 a)       b)          c)    d)  
 
Figure IV. 1: Morphology of colon cancer cell lines. Cells were cultured in their recommended media for 
one week. Photographs were taken two days after the last passage, time sufficient to allow adherence. a) 
squamous cells (HCT 116) b) spindle shaped cells (SW-480) c) semi-adherent/floating cells (Colo-206F) d) 
compact cloudlets of cells (HT-29A3). Yellow bar represents 100μm and is common for a), b), c), d).  
 
IV.1.2 Colon cancer cells proliferation 
We calculated the doubling times of given cell lines and the values were spanning 
from as high as 41,6 hours for Colo-206F cells to the lowest in HCT 116 and DLD-1 cells 
that doubled their populations in 17,7 and 17,1 hours respectively (fig. IV. 2 b)). Colon 
carcinoma cell lines showed generally lack of contact inhibition and were capable to 
continue growth even after reaching monolayer (fig. IV. 2 a)) . 
 
a)     b)      
 
Cell line 
Doubling time in common medium 
[h]                              σ 
HT-29A3 35,0                          2,1 
LoVo 23,8                          1,8 
Colo-206F 41,6                          2,6   
SW 480 40,9                          3,4 
HCT 116 17,7                          0,9 
DLD-1 17,1                          1,1 
LS-174T 26,2                          2,2  
RKO 19,0                          0,9  
Figure IV. 2: Proliferation of colon cancer cells. a) HCT 116 colon carcinoma cells grown in culture for 5 
days without passaging. After reaching confluence, cells continued to grow in more layers. Yellow bar 
represents 100μm. b) Doubling times of cell lines calculated from cell count increments after 48 hours in 
culture. All cell lines were sub-confluent at the time of final cell counts evaluation. The estimation of 
doubling time for each cell line was repeated several times and the average values with standard deviations 
are shown.  
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 IV.1.3 Sensitivity of colon cancer cells to TRAIL-induced apoptosis  
Next we examined whether and how are cells from this panel sensitive to 
TRAIL-induced apoptosis induced with the recombinant TRAIL under our standard 
cultivation conditions. For the detection and quantification of TRAIL-induced apoptosis we 
used AnnexinV-FITC-based flow cytometry analysis. Cells were treated with six different 
concentrations of TRAIL diluted in corresponding cultivation media. To reveal the kinetics 
of apoptosis, the experiment was parallelly performed at two time points, by adding the 
TRAIL in a reverse manner 15 and 6 hours prior to Annexin V-FITC staining and flow 
cytometric analysis.  
While RKO cells were markedly resistant to even high concentrations of TRAIL, 
other cell lines demonstrated moderate to high sensitivity beginning at TRAIL 
concentrations as low as 20 ng/ml. The average values of FITC-positive fraction of 
technical duplicates are summarized in fig. IV. 3 a)  
In addition to the Annexin V-FITC staining of the phosphatidyl serine externalized 
on apoptotic cells we used Caspase-Glo 3/7 Assay as additional methods for the 
quantification of TRAIL-induced apoptotic signaling. This method is based on the 
quantification the activated effector caspases and reflects the initial efficacy or robustness 
of their undirect activation by TRAIL. Activaty of the effector caspases measured after 3 
hours of incubation with TRAIL and in principle followed the sensitivity profiles obtained 
by flow cytometry. Low sensitivity of RKO in comparison with other cell lines was 
confirmed. In addition caspase test revealed low activation of caspases after 3 hours of 
treatment in HT-29A3 cell line.   
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Figure IV. 3: Apoptosis of colon cancer cell lines cultivated in standard conditions (flow cytometry).  
a) Eight colon carcinoma cell lines were grown under standard conditions in corresponding cultivation media. 
TRAIL diluted in the respective media to concentrations from 10 ng/ml to 500 ng/ml was added to sub-
confluent cells 15 or 6 hours prior to processing of cells for flow cytometry. Blue and red bars represent 
averages of annexin V FITC+ fractions of technical duplicates of 6-hour treatment and 15-hour treatment 
respectively. b) Example of gating and processing raw FACS data. Left: debris and conglomerates are 
excluded in scatter dot-plot, single cells (gate) are taken for further evaluation, (LoVo cells, annexin V FITC 
staining).   
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Figure IV. 4: Apoptosis of colon cancer cell lines cultivated in standard conditions (caspase 3/7 assay).  
Eight colon carcinoma cell lines were grown under standard conditions in their recommended media. TRAIL 
diluted in the respective media to concentrations from 20 ng/ml to 500 ng/ml was added to sub-confluent 
cells 3 hours prior to processing of cells for luminescence-based quantification of caspase 3/7 activation. Bars 
represent averages of relative luminiscence units (RLU) of biological duplicates. 
 
IV.2 Influence of cultivation conditions on the behavior of colon 
carcinoma cell lines  
IV.2.1 Morphology of cells is mostly changed in NS-Ac serum-free 
defined medium  
 Cultivation of breast and other cancer cells in the defined, serum-free medium, 
originally introduced to support growth of neural stem cells (NS-Ac), allows formation of 
so-called spheroids and was reported to allow preferential growth of less differentiated, 
progenitors or stem cells resembling tumour cell cultures (Ricci-Vitiani et al., 2007). We 
used this growth conditions for our panel of colorectal cell lines and compared it (both 
morphologically and functionally) with their cultivation under the standard conditions. We 
have observed significant shift in morphologies of all studied cell lines cultivated in NS-Ac 
medium. In general, cells tended to aggregate, while simultaneously in most cases, their 
adherence to surface was compromised. Consequently, increased number of floating of 
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cells and switching of shape from spindle to round was observed in several cell lines. When 
seeded at clonal concentrations, cells stayed together as they proliferated, and eventually 
adhered to other growing clones in their proximity.  
Particularly two cell lines, HCT 116 and HT-29A3, (fig. IV. 5 a)) showed a 
prominent ability to form compact spheroid bodies. Unlike other clusters, spheroids were 
compact, rounded and almost uniformly sized formations which emerged all at once, 
usually on day 2 to 4 of cultivation in NS-Ac, depending on initial cell concentration.  
In some prolonged serum-free cultivations, we observed rare spheroid-like clusters 
even in other cell lines including LoVo, COLO-206F and SW 480 (fig. IV. 5 b)). Since the 
definition of spheroid body is arbitrary, they might represent either the same entity or 
artifact.  
 
IV.2.1.1 Contributions of selected components from NS-Ac media to morphologic 
changes of cultivated cells 
To determine which component of the NS-Ac media is pivotal for these dramatic 
morphological changes of examined cells, we used different combinations of NS-Ac 
components, serum and cultivation plastic labware. Except for Colo-206F, usage of 
non-cell culture-treated dishes did not seriously compromised cell adherence. The only 
factor necessary but not sufficient for enabling spheroid growth was the commercial 
proliferation supplement most likely containing (apotransferrin, insulin, putrescin, 
selenium, and progesterone) While supplementation with EGF and bFGF was not necessary 
for spheroids initiation itself, it enhanced their growth, resulting in larger diameter of the 
final spheres (fig. IV. 5 c)).  
When added, serum caused reversal to normal adherent phenotype in all cases, 
irrespectively of presence of proliferation supplement, growth factors and heparin (data not 
shown). 
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b)       c)  
         
Colo-206F LoVo
 
GFs - GFs +
Figure IV. 5: Changes in cellular morphologies of colon cancer cell lines during cultivation in NS-Ac 
medium. a) Cells were cultured in the regular versus NS-Ac medium for six days. Passages were performed 
when needed to prevent their confluence. Upper rows in both portions show normal phenotype, lower rows 
show modified phenotypes in NS-Ac medium. b) Colo-206F and LoVo cell lines formed rare spheroids when 
cultured in NS-Ac for prolonged periods (two weeks). Left: Colo-206F shperoids are surrounded by rest of 
cells and cellular debris. Right: red arrow points to putative LoVo spheroid. c) Effect of EGF and bFGF 
supplementation on spheroids (HT-29A3, 6 days in NS-A). Yellow bar represents 100μm in a), b), c).   
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IV.2.2 Cultivation in NS-Ac medium attenuates proliferation of colon 
carcinoma cell lines 
Side-by-side comparison of cells cultivated under the standard and serum-free 
(NS-Ac medium) conditions indicated that their proliferation in the NS-Ac serum-free 
medium might be attenuated. Calculation of the doubling times revealed their averaged 25 
% increase in the population doubling time, which was most apparent in fast proliferating 
and sphere forming HCT 116 cells (45% increase) (Figure IV. 6).  
 
Cell line 
Doubling time in regular medium 
[h] 
Doubling time in NS-Ac medium 
[h] Increase
HT-29A3 35,0 42,1 20 % 
LoVo 23,8 28,7 21 % 
Colo-206F 41,6 48,6 17 % 
SW 480 40,9 54,0 32 % 
HCT 116 17,7 25,7 45 % 
DLD-1 17,1 21,7 27 % 
LS-174T 26,2 33,0 26 % 
RKO 19,0 23,5 24 % 
 
Figure IV. 6: Doubling times of colon cancer cells cultivated in the regular and serum-free medium. 
Doubling times of cell lines calculated from cell count increments after 48 hours in culture. All cell lines were 
sub-confluent at the time of final cell counts evaluation. Experiments were repeated several times with similar 
results.   
 
IV.2.3 Serum-free cultivation effect on TRAIL-induced apoptosis  
We employed M30 FITC flow cytometry approach to measure TRAIL-induced 
apoptosis, resp. TRAIL-induced activity of the effector caspase-3 of colon carcinoma cell 
lines grown in the serum-free versus regular cultivation media. While in majority of cell 
lines their cultivation in NS-Ac medium compromised their sensitivity to TRAIL, in others 
(LoVo, Colo-206F) the effect was opposite. RKO were exceptionally negative for M30 
FITC (presence of caspase-3-cleaved cytokeratin 18) signal, and were thus considered 
principally immeasurable by this method (fig. IV. 7 a)). 
Next we decided to verify sensitivity of cells to TRAIL-induced apoptosis after 
differential cultivation by annexin V FITC staining. For this experiment, we chose three 
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highly to moderately TRAIL-sensitive cell lines, DLD-1, HCT-116 and HT-29A3, 
regarding their previously observed distinct capability of forming spheroid clusters. 
Annexin V-FITC staining of the analyzed cells confirmed the data obtained using the M30 
FITC assay (fig. IV. 7 b)).     
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Figure IV. 7: TRAIL-induced apoptosis of colon cancer cell lines grown under different cultivation 
conditions.  a) M30 FITC flow cytometric evaluation of analyzed cells was carried out after their 2-hour 
incubation with TRAIL. Cells were parallelly cultured in their regular media (blue bars) or NS-Ac (red bars) 
for six days. Bars represent averages of technical duplicates. RKO cells were repeatedly proved to be 
negative in M30 FITC assay. b) Annexin V FITC flow cytometric verification of differential TRAIL 
sensitivity of selected cancer cell lines. All cells were sub-confluent at the time of processing in both 
experiments.    
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IV.2.4 Cell surface receptors profiling of colon cancer cells grown under 
different cultivation conditions  
Changes in growth media implemented TRAIL-induced apoptosis of colon cancer 
cells might be related to changed expression of its proapoptotic receptors. In addition these 
different cultivation conditions might affect cell surface of additional, stem cells-related 
markers. Thus in the next set of experiments we undertook comparative analysis of their 
expression. 
 
IV.2.4.1 Expression of CSC markers 
By means of PE labeled mABs staining and subsequent flow cytometry, we 
measured surface expression of CD133 and ABCG2, proteins commonly associated with 
CSC immunophenotype.  
We initially performed comparison of two commercially available conjugates 
AC133 and 293C3, recognizing two reputedly distinct glycosylated CD133 epitopes, to 
determine their utilization in following analyses. Minimum difference was found between 
staining of cells surface expressed CD113 with these two antibodies. Cell lines were either 
completely CD133 positive (namely HCT 116, HT-29A3, LoVo, Colo-206F), negative 
(LS-174T), or negative with a small subset of positive cells (DLD-1, RKO, SW 480) (fig. 
IV. 8 a)). The minor positive subsets were mainly significant in DLD-1 cell line, in which 
they occurred repeatedly in following measurements, and represented approximately 
17-22 % of population. This was not the case in RKO and SW 480 cell lines, in which 
positive subsets were less abundant and recognized only by 293C3 clone. Considering the 
differences between staining with AC133 and 293C3 mAbs neglectable, we further used 
only AC133 mAb for staining of CD133.  
Next we analyzed whether our two different cultivation conditions will have an 
effect on the cell surface expression of putative CSC markers CD133 and ABCG2. 
Following 6-day long cultivation in NS-Ac, CD133 levels (quantified by AC133 staining) 
were higher in one half of the tested cell lines, whereas the second half had none or a slight 
negative shift in AC133 signal following the their cultivation in NS-Ac medium. ABCG2 
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was strongly expressed only in LoVo cells, and was reproducibly upregulated under the 
serum-free cultivation conditions. Low expression of ABCG2 was found also in HT-29A3 
and RKO cells and was slightly increased in cell grown in serum-free medium (fig. IV. 9). 
We were interested whether capability of spheroid formation might be correlated to 
CD133 phenotype. HCT116 and HT-29A3 are both strongly CD133 positive and form 
spheres very efficiently, while CD133 negative LS-174T never formed spheres in our 
hands. We summarized possible correlations in fig. IV. 8 c). 
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b)       c) 
 
      
cell line AC133+ Spheroids
HT-29A3 Y Y
HCT 116 Y Y
LoVo Y P
Colo-206F Y P
DLD-1 P N
RKO N N
SW 480 N N
LS-174T N N
Figure IV. 8: CD133 in colon carcinoma cell lines. a) Flow cytometric analysis of two CD133 epitopes in 
colon cancer cell lines. Analysis was performed on sub-confluent cells cultured under the standard cultivation 
conditions and their recommended media for maximum ten days after thawing. Red histogram contours 
represent respective values of samples, blue histogram contours represent unstained negative controls. b) 
Example of processing raw FACS data (293C3 mAb PE, DLD-1 cell line) c) Correlation of AC133+ 
phenotype with capability of spheroid formation. For better comprehension, values were arbitrarily 
simplified. (Acronyms: Y - yes, N - no, P - partially). 
IV.2.4.2 Effect of serum-free cultivation conditions on cell surface expression of death 
receptors 
To determine whether or not the change in sensitivity to TRAIL-induced apoptosis 
after differential cultivation was caused by different expression profile of death receptors, 
we analyzed the expression of DR4, DR5 and Fas and TNFR I by flow cytometry. As 
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comparison of cells isolated from primary tumors to those from metastases would be 
valuable, we also extended the set of tested cell lines for CX-1 and SW 620 that are related 
to HT-29A3 and SW 480 respectively and derived from metastatic syngenic tumors. 
Primary HT-29A3 and SW 480 share with their metastatic counterparts most of 
morphological features and are practically unrecognizable in culture. We found analogies 
also in spheroid forming and proliferation rates.      
 The expression of death receptors DR4, DR5 and Fas was increased in eight of ten 
cell lines after cultivation in NS-Ac medium. In our hands, TNFR I wasn’t proved strongly 
expressed on any of ten cell lines. In the two metastasis-derived cell lines (CX-1, SW 620) 
death receptors were not upreagulated, and Fas profiling showed a minor decrease in CX-1 
and RKO (fig. IV. 9).  
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Figure IV. 9: Phenotype of colon cancer cells depending on cultivation conditions. The expression of 
death receptors DR4, DR5, Fas and TNFR1 and putative CSC markers AC133 and ABCG2 was analyzed by 
flow cytometry in ten colon cancer cell lines. Cells were cultured in parallel in their recommended media 
(blue bars) and NS-Ac (red bars) for six days. Cell lines were passaged as necessary when nearing 
confluence; all cells were sub-confluent at the time of processing. Values of staining negative controls (GaM 
PE) were used as the reference for plotting the relative expression of analyzed cell surface markers. 
Experiments were repeated several times with similar results.     
 56
IV.3 Influence of fibroblasts on TRAIL-induced apoptosis in colon 
carcinoma cell lines 
The cultivation conditions widely used in the eukaryotic cell biology do not even 
come slightly close to the situation in organisms, e.g. of cancer cells grown in the tumor 
environment. It also became recently reported that the neighboring cells e.g. stromal 
fibroblasts can influence phenotype of other co-cultivating cells and even induce in them 
changes leading to de-differentiation (Lacina et al., 2007). Thus in the line with this 
interesting data we were interested whether and how could co-cultivation of fibroblasts 
(both stromal-derived and normal ones) with colorectal cancer cells influence 
TRAIL-induced apoptosis the later ones. 
 
IV.3.1 Labeling of cells with fluorescent dyes 
IV.3.1.1 Labeling of fibroblasts with CellTracker Red CMTPX  
The first important technical aspect of this assay was to distinguish the colon cancer 
cells from the feeder fibroblasts allow thus their molecular and functional analysis. We 
were not able to sort out fibroblasts from tested cancer cells on scatter plots; therefore we 
decided to use red fluorescent dye CellTracker Red CMTPX for labeling of fibroblasts used 
as feeder cells. Firstly, this would allow us to continue measuring apoptosis by 
annexinV-FITC, secondly we would minimalize the potential toxicity of the label to the 
tested cells. 
Since we needed a labeling that would remain unchanged for several days we have 
verified the manufacturer’s claims that CMTPX is stable when properly used. However 
initial testing of mixtures of labeled and plain cells by flow cytometry rendered repeatedly 
an illegible outcome leaving us with the suspicion that CMTPX staining might be leaky 
(data not shown).  
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IV.3.1.2 Preparation and characterization of stable, fluorescent proteins-expressing 
transfectants of colon cancer cell lines  
In another approach that might allow distinguishing feeder and tumour cells we 
tested labeling the tumor cells with the recombinant lentiviral vector expressing RFP. 
Although successfully prepared, numerous clones selected from RFP expressing mixed 
cultures were unstable and ceased to express RFP for yet unknown reasons (data not 
shown). The experiment design was therefore reduced to single DLD-1 clone E8 that 
remained positive for RFP expression in long-term culture.  
Clone E8 was characterized for its sensitivity to TRAIL in a comparison to the 
original DLD-1 cells (fig IV. 10). Since DLD-1E8 requires permanent selection pressure of 
puromycin, which would cause bystander killing of fibroblasts during their co-cultivation, 
we have verified DLD-1E8 reactions to temporary absence of puromycin. In contrast to 
maternal cell line, DLD-1E8 clone under puromycin selection demonstrated mild resistance 
to TRAIL, which could be reversed by withdrawal of puromycin. We confirmed visually 
(data not shown) and later by flow cytometry, that even without puromycin DLD-1E8 cells 
were able to maintain the required RFP expression for at least one week.   
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Figure IV. 10: Properties of DLD-1E8 RFP expressing cells. a) Comparison of sensitivity to TRAIL of 
DLD-1E8 clone and maternal DLD-1 cell line. Bars represent averages of technical duplicates. b) DLD-1E8 
cells in co-culture with normal human fibroblasts. Cells were not under puromycin selection when 
photographs were taken due to puromycin-sensitive feeder layer. In both rows, left photograph shows cells in 
fluorescent spectra; and the right photograph then the same region taken as phase contrast under normal 
illumination. Yellow bars represent 100μm.    
 
IV.3.2 Fibroblast conditioned media may regulate TRAIL-induced 
apoptosis 
The feeder cells (in our case normal and stromal fibroblasts) might affect the 
co-cultured cells in several ways. They can soluble factors as cytokines and in-trans change 
properties of co-cultured cells with expressed receptors for these factors. In addition to the 
soluble, secreted factors, direct cell-to-cell contact could influence properties and behavior 
of co-cultured cancer cells.  
To determine if fibroblasts produce soluble factors which would influence apoptosis 
sensitivity of selected colon cancer cell lines DLD-1 and HCT 116, we tested apoptosis of 
cells cultivated with media conditioned by human fibroblasts and cancerous stromal 
fibroblasts derived from three different skin tumors (basal cell carcinoma, spinal cell 
carcinoma and benign fibrous histiocytoma) (tab. III. 1. ). Experiment was performed in 
two cultivation time points (1 day (Figure IV. 11 a)) and 3 days (Figure IV. 11 b)) ), 
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while media were not replaced until adding of TRAIL; 6-hour treatment with TRAIL was 
used. We observed only minor differences between cells cultivated in conditioned media 
compared to those in unconditioned controls. A potentially small decrease in apoptosis was 
found in both DLD-1 and HCT 116 cells after cultivation with conditioned media of S4 and 
HF. This decrease was more obvious in HCT 116 than DLD-1 cells after 1-day cultivation 
and faded after 3-day cultivation in both cell lines. Conversely, media conditioned by B3 
and B4 seemed to compromise survival of colon cancer cell lines. This effect occurred even 
in controls untreated with TRAIL, hence was considered unspecific.     
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Figure IV. 11: Influence of fibroblasts-conditioned media on TRAIL-induced apoptosis of colon cacer 
cell lines.  a) 1-day cultivation in conditioned media from human and stromal fibroblasts.  b) 3-day 
cultivation in conditioned media from human and stromal fibroblasts. At both time points, cells were seeded 
in lower densities to prevent soon reaching of confluence. Media were conditioned for 1 day in cultures of 
confluent fibroblasts. Before adding to cancer cells, conditioned media were mixed in 1:1 ratio with fresh 
media recommended for respective cell lines. Bars represent averages of technical duplicates.   
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IV.3.3 Effect of direct co-cultivation of colon cancer cell lines with 
fibroblasts on their TRAIL-induced apoptosis. 
To determine if direct contact with stromal or normal fibroblasts can regulate 
TRAIL-induced apoptosis, we performed two types of direct co-cultivation experiments. 
First, we employed the DLD-1E8 clone expressing RFP enabling distinction of measured 
cells from feeders on FACS. Cells were cultured together with feeder cells (HF, B4, B3, 
S4) for 3 days without puromycin. 
Flow cytometric analysis with use of annexin V FITC staining revealed no profound 
protective effect of any feeder type on DLD-1E8 cells. Neither fibroblasts HF and S4 
suspected of anti-apoptotic effect in previous experiment demonstrated any clear protection 
from TRAIL in DLD-1E8 (fig IV. 12d)). Since it was reported that puromycin may have 
influence on apoptosis, and these concerns were supported by our preliminary testing (fig 
IV. 12a)), we measured negative controls without puromycin as well. 
In an another approach we analyzed whether co-cultivation of colon cancer cells 
with fibroblast would in any way affect TRAIL-induced activation of the effector caspases 
in the Caspase3/7 GLO assay. Both normal and stromal fibroblasts by themselves are 
resistant to TRAIL-induced apoptosis and did not show any signs of the effector caspases 
activation (fig IV. 12b and data not shown). HCT 116 and DLD-1 cell lines directly co-
cultured with complete set of fibroblast types. Cells were seeded on confluent feeders 3 
days before adding TRAIL. Cells were incubated with TRAIL in two time scales (2 and 6 
hours). Concerning influence of feeders in different incubation times and TRAIL 
concentrations we have not found any unequivocal trend. When normalized to respective 
negative controls, activation of the effector caspases was lower in cell co-cultured with S4 
fibroblasts in both colon cancer cell lines. Similar effect of B3 feeders was observed in case 
of DLD-1, while in HCT 116 this was rather restricted to 2-hour treatment (fig IV. 13). 
Thus in these initial experiments we did not observe any significant direct or indirect effect 
of either normal or cancer-derived, stromal fibroblasts on TRAIL-induced apoptotic 
signaling in colorectal cancer-derived cell lines. However, at least some tested feeder 
fibroblasts as spinocellular carcinoma-derived S4 showed at least some (inhibitory) effect 
on TRAIL-induced apoptotic signaling and also these experiments were done only on 
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selected colon cancer cell lines. Thus, they need to be repeated on the entire panel of other 
cell lines and using additional methodical approaches.
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Figure IV. 12: Apoptosis in DLD-1E8 cells after direct co-cultivation with fibroblasts (flow cytometry). 
a) Pure E8 cells were analyzed for TRAIL-sensitivity depending on selection agent puromycin. Cells were 
either kept under puromycin (3 μg/ml) selection during cultivation and treatment with TRAIL - until 
processing for Annexin V FITC staining; (entitled E8 PURO+) or puromycin was withdrawn from the 
cultivatiom medium 2 days before treatment of cells with TRAIL; (entitled E8 PURO-). b) Verification of 
resistance of feeder fibroblast cells to TRAIL by Annexin V FITC on FACS. TRAIL (concentrations 0; 
20; 200 ng/ml) was used for 15-hour treatment. Similar results were obtained with all fibroblasts used (B4, 
B3, S4, HF). Results from annexin V FITC staining were further confirmed by M30 FITC assay (not shown). 
c) TRAIL-induced apoptosis in direct co-culture of E8 cells with B4 fibroblasts used as feeders; (example of 
processing FACS data). d) E8 cells cultured with/without confluent fibroblasts for 3 days were treated with 
TRAIL in timescale from 6 to 15 hours and analyzed by flow cytometry on annexin V FITC staining. Bars 
represent averages of technical duplicates.  
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Figure IV. 13: TRAIL-induced apoptosis of HCT 116 and DLD-1 cells after co-cultivation with stromal 
fibroblasts (caspase 3/7 GLO assay).  HCT 116 and DLD-1 cells were co-cultured with normal human 
fibroblasts (HF), stromal fibroblasts from spinocellular carcinoma (S4), basalioma (B3) and benign fibrous 
histiocytoma (B4). Cells were seeded on plates with confluent fibroblasts and plain plastic as a negative 
control 3 days b) before treatment with TRAIL. TRAIL was added diluted in fresh media in concentrations 
20 and 200 ng/ml. Cells were processed after a) 2-hour b) 6-hour treatment. Bars represent average RLU 
values of technical duplicates normalized to RLU values of respective untreated controls.      
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V. Discussion 
 
When thinking of tumorigenesis, several seemingly easy but fundamental questions 
have not been answered so far. Especially, our apprehension of the very first step of tumor 
initiation is based mainly on indirect data and only recently we became aware of the 
importance of microtumor environment for the initiation and progression of tumorigenesis. 
Therefore any novel consequences may ultimately lead to complete shift of current 
paradigm. Nowadays, there is no question that cancer is a genetic disease that starts from a 
single cell. However, at least in carcinomas, it is more and more likely that not mutations 
per se but rather combination of acquired genetic and epigenetic changes within the cells 
and their interaction with surrounding cells and also avoidance of the immune response  
actually must cooperate for the successful tumor initiation (Baylin and Herman, 2000; van 
Zijl et al., 2009). Extrapolating the recently reborn cancer stem cells (CSCs) hypothesis in 
this manner may generate verifiable predictions which we took into account when 
designing our experiments.  
CSC hypothesis implies that cancer cells are heterogeneous in their self-renewal 
capacity and, contrary to what clonal evolution theory assumes, this is associated with 
hierarchy. Together, this predicts a pivotal population of CSCs and heritability of its 
exclusive traits. The central question of our work was, whether we would be able to (i) 
observe such heterogeneity in cancer cell lines, and eventually, (ii) examine their 
sensitivity/resistance to TRAIL-induced apoptosis. Many would object that cell lines are 
not suitable model for studying CSCs as cultivation of cells for prolonged period leads to 
expansion of fast proliferating possibly non-CSC clones, and cancer cells with SC-like 
properties may therefore vanish from such cultures after a number of passages. Although 
these concerns seem well-founded and fresh tumors remain the primary source of CSCs for 
their characterization, our current insight into social context of cancer cells is too limited 
and many groups have obviously isolated the CSC entity from established cell lines (Dou et 
al., 2007; Charafe-Jauffret et al., 2009). Moreover, utilization of cancer cell lines may be 
advantageous, since cell lines unlike tumors do not have any contaminating normal stem 
cells that quickly differentiate under the normal culture conditions (Kondo, 2007).  
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We have analyzed eight colon carcinoma cell lines for their morphological and 
biochemical changes imposed by the spheroid assay (SA) cultivation conditions. SA was 
originally developed for characterization of normal tissue stem cells and has recently been 
used for enrichment of putative CSCs from solid tumors in many studies (Galli et al., 2004; 
Grimshaw et al., 2008; Inagaki et al., 2007; Ricci-Vitiani et al., 2007). In general, we 
observed morphology of most tested cell lines was seriously influenced and notably some 
cell lines including HCT 116 and HT-29A3 demonstrated capability of forming spheres or 
spheres-like structures. We haven’t verified the tumor initiating capacity of sphere-forming 
cell lines in-vivo; still our results suggest at least promising morphological analogies with 
stem cells exist in some cell lines. One thing that must be taken into consideration when 
interpreting the spheroid assay is that there is little definitive information as to which cells 
are being propagated. For example, in neurosphere assay, so far best-studied sphere model, 
it has been shown that neurosphere frequency approximates progenitor cell activity more 
closely than stem cell activity (Marshall et al., 2007). Moreover, after dissociation of 
neurospheres and their subsequent re-plating more than 90% of cells die which suggests 
that spheres are also implicitly heterogeneous (Reynolds and Rietze, 2005). Thus we were 
aware of this fact and considered spheres as the changed environment for the selected cell 
lines due to their 3-D structure more resembling actual original tumor and not as a source 
of completely more progenitor-like cancer cells. Another related puzzling issue about 
spheroids is the very mechanism of their emergence and maintenance. Undisputed is the 
effect of serum withdrawal that makes cell aggregation easier and this effect seems rather 
nonspecific. Nevertheless, creation of the round-shaped aggregates is presumably 
accompanied by cytoskeleton remodeling and one may expect that also specific 
intercellular junctions and signaling are being active within the spheres. Finally, the pivotal 
distinguishing feature must be undoubtedly overcoming the anoikis. It has been suggested 
that only cells responsive to EGF and bFGF are supported for survival, whereas the 
unresponsive differentiated cells die early on mainly via induction of apoptosis (Reynolds 
and Rietze, 2005). However, we have not observed any excessive dying of cells of any cell 
line upon seeding in NS-Ac medium; moreover we have shown that EGF and bFGF are not 
strictly required for the formation of spheroids but for their maintanace and might also limit 
number of cells within these spheroids. Based on these observations we speculate that: (i) 
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cells of cancer cell lines may get along the restrictive conditions despite not all being bona-
fide cancer stem cells. Providing that cancer cell lines were derived from single cancer 
cells/cancer stem cells (if CSC theory would be applied) they may all posses at least some 
degree of stem-like properties. Alternatively, transformed phenotype and adjustment to 
artificial in-vitro conditions provide sufficient fitness for survival even in serum-free 
medium, (ii) slower proliferation of cells within spheroids could be a sum of a number of 
influencing factors including denial of some serum-based ones  (Satoh et al., 1996), less 
efficient accessibility of cells within spheres to nutrients or by non-optimal composition of  
the NS-Ac media (/proliferation supplement).  
In order to prove “stemness” and namely self-renewal, not actually primary but 
secondary, tertiary and higher orders sphere formation is required. Indeed, it is of interest to 
investigate why at all CSCs as well as normal stem cells are enriched in the spheres. It has 
been reported previously, using sphere assay, that that Hedgehog-Gli signaling is 
implicated in regulating the self-renewal and tumorigenesis of CD133+ CSCs in gliomas 
(Clement et al., 2007). In one recent study EGF receptor signaling has been shown to 
synergize with Hedgehog (hh)/Gli in oncogenic transformation (Schnidar et al., 2009). 
Taken together, EGF-Hedgehog self-renewal axis might serve as a connection link between 
CSC and their maintenance in spheroid cultivation. Our experiments with omitted EGF 
were too short to explore possible terminating effect on self-renewal; in fact we have never 
passaged the spheres more than 3 times for purely pragmatic reasons. We also cannot 
exclude a possibility that the examined colon cancer cell lines produce by themselves low 
but sufficient amount of the necessary growth factors including EGF that would allow for 
their survival and limited proliferation. We will surely address this topic in our future 
experiments. 
We have investigated the surface expression of death receptors and stem cell 
markers CD133 and ABCG2, how it changes in relation to differential cultivation, and 
eventually if this influences the TRAIL-induced apoptosis. Surprisingly, CD133 (CD133-1 
epitope) was strongly expressed by all cells of some cell lines (HCT 116, HT-29A3, LoVo) 
while it was completely absent in others (RKO). This is in contrast to results usually 
obtained in fresh tumor samples, where stem cell marker expression tends to be much more 
heterogeneous, and marker-positive subsets are often minor (Ricci-Vitiani et al., 2007). Our 
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results suggest that cell lines derived of one cancer cell maintain its original marker 
expression profile, perhaps even related hierarchical status. However, to claim that some 
cancer cell lines more or less represent clones of CSCs, while other do not, would be very 
controversial and a clear over-interpretation at this point. Even so  we could delineate some 
correlation between AC133+ phenotype and efficacy of spheroid formation as all spheres 
were formed in AC133+ cell lines (HCT 116, HT 29A3) and conversely, none of AC133- 
cell line (DLD-1, RKO, LS-174T) formed spheres in our hands. However, not all AC133+ 
cell lines (LoVo, Colo 206F) formed spheres, although some rare cases were noted in 
prolonged cultivations. In addition to this, DLD-1 cell line has perhaps the most interesting 
phenotype as it maintains almost stable subset of AC133+ cells wobbling from 17 % to 25 
% of all cells, which was verified repeatedly by flow cytometry. It has been recently 
described in literature, that DLD-1 cell line retains CSC-subpopulation, which is i.a. 
characterized by high expression of Nanog, CD44 and downregulation of CK20 (Ferrand et 
al., 2009). These findings may oppose our previous suspicion: not only may the cancer cell 
line represent uniform hierarchal caste but it may further develop its own internal 
hierarchy. Besides recognizing CD133 phenotype as a potential determinant of cell 
morphology during serum-free cultivation, we found that NS-Ac alone influenced the 
surface expression of CD133, or precisely its AC133 epitope. Among the AC133+ cell 
lines, Colo 206F and CX-1 showed remarkable increase in AC133 expression (+48 % and 
+106 % respectively), while only minor increase was observed in LoVo and mild decrease 
in HCT 116 and HT-29A3 cell lines. This result either indicates that enrichment in stem 
cell-like entity during serum-free cultivation is not obligate, or using of AC133 as a marker 
is misleading. AC133 was also relatively markedly upregulated in RKO and DLD-1 cell 
lines (+106 % and +74 % respectively). In DLD-1 increase was marginal with unchanged 
proportion of AC133+ subset. Mainly in case of AC133- cell line RKO, biological 
significance of AC133 epitope upregulation is umbrageous, because the absolute change 
seems neglectable. All in all we walk into question, as to what is the relation between 
AC133, differentiation and spheres. At present, lack of information on physiological 
function of CD133/prominin-1 together with fact that we performed only one set of 
experiments complicates the proper interpretation of our results. At least promising indicia 
emerged from a recent study by Qiang et al., (2009), that prominin-1 is involved in 
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cytoskeleton alteration and function of glycogen synthase kinase 3 (GSK3), pivotal protein 
in self-renewal regulation.. We will undoubtedly modify our experimental setup in order to 
gain more reliable statistical data. In addition, performing inverse experiment, based on 
returning the cells into their regular growth media after cultivation in NS-Ac will address 
the findings of Vodianik (2005) and others that differentiation decreases the level of 
CD133 protein.  
Strong surface expression of another often used CSC marker ABCG2 transporter 
was detected only in LoVo cell line and it was even increased after cultivation of LoVo 
cells in NS-Ac. Other cell lines demonstrated only low (HT 29A3, RKO) or none 
expression of ABCG2. Our observation is in accordance with previous studies in which 
EGF was described to significantly upregulate ABCG2 expression in cytotrophoblasts, 
BeWo and MCF-7 cells (Meyer zu Schwabedissen et al., 2006). 
As TRAIL-induced apoptosis appears to be closely connected to the 
regulation/protection from tumorigenesis, at least at the metastatic progression, and this 
system is also recently being explored for cancer therapy, the obvious question for us was if 
and how the cultivation conditions affect TRAIL-induced apoptotic signaling in analyzed 
colon cancer cell lines. Several studies suggested TRAIL as a potential component of 
immune surveillance, and especially, of anti-metastatic mechanisms (Cretney et al., 2002; 
Grosse-Wilde et al., 2008). Moreover, an elegant study of Mani has recently linked 
epithelial-mesenchymal transition (EMT) to acquisition of cells of stem cell properties 
(Mani et al., 2008). Whereas EMT is regarded as crucial step enabling cancer to 
metastasize, it might also play a role in the initial phases of tumorigenesis, so we 
anticipated that TRAIL might consequently play role in early stages of tumorigenesis by 
killing cancer stem-like cells. In addition, some clues supportive of this assumption have 
already occurred in literature (Sussman et al., 2007). 
Flow cytometric analyses performed on ten colon cancer cell lines from normal 
cultivation versus serum-free cultivation, pointed out generally elevated levels of surface 
TRAIL-R1 (DR4), TRAIL-R2 (DR5) and Fas (CD95) in most cell lines grown under the 
serum-free conditions, while outcomes of TNFR1 were considered rather neglectable. After 
serum-free cultivation, DR5 was most upregulated in RKO cells, while DR4 as well as Fas 
mainly in SW 480 and LoVo cell lines. Instead of complete listing of changes in individual 
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cell lines, let’s concentrate on important patterns and eventual deduction of their origins. 
First of all, the fact that in several cell lines at least some death receptors are not 
upregulated, suggests that the effect of serum-free conditions is not unspecific (e.g. 
metabolic). For instance, Fas was nearly 41 % down after cultivation without serum in 
RKO cells. As far as the upregulation of DR5 is concerned, it has been described in 
literature that NF-kB may be involved. Interestingly, according to one recent study, NF-kB 
activation discriminates the character of signals in order to either upregulate DR5 or not 
(Shetty et al., 2005). While both etoposide and EGF activated NF-kB pathway, only 
etoposide was shown to increase the level of DR5, since unlike of EGF, etoposide did not 
recruit histone deacetylasse 1 (HDAC1) to the DR5 gene. This is fuelling our speculations, 
that EGF dependant NF-kB activation might (purely hypothetically) also be the cause of 
DR5 shift, provided that HDAC1 was for any reason inactivated. We suggest that we 
should perform extended experiments, either by withdrawing EGF from NS-Ac or 
simultaneous measuring of HDAC1 activity prior to measuring the death receptors. 
Particularly for measuring the effect of serum-free conditions on the phenotype of cancer 
cell lines, we widened the set of cell lines for CX-1 and SW 620, metastatic relatives of 
HT-29A3 and SW 480 respectively. We have observed a striking similarity in behavior of 
CX-1 and SW 620 in comparison to their primary tumor-derived counterparts, and that was 
almost untouched expression profile of all tested markers after serum-free cultivation. It is 
a tempting idea that this is due to a selection of cells during the metastasizing, which 
prefers cells adjusted to overcoming anoikis and restrictive conditions. These cells 
therefore do not need to undergo further phenotype changes to get along with NS-Ac. In 
support of such concept is a recent finding of Laguinge et al. (2008) that DR5 mediates 
anoikis in human colorectal carcinoma cell lines.   
Upregulation of death receptors during the SA is what one would anticipate when 
assessing TRAIL as a selective anti-CSC agent. However, our data obtained from 
measuring the TRAIL-induced apoptosis were rather contradictory. To sum up, we have 
employed several principal approaches for the assessment of TRAIL-induced apoptosis, 
including two based on flow cytometry (M30 FITC, annexin V FITC staining) and also 
different time scales all confirming that in most colon cancer cell lines (except for LoVo 
and Colo-206F) their cultivation in the serum-free NS-Ac medium compromised the 
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TRAIL-induced apoptosis. We have not found any reliable correlation between spheres and 
TRAIL resistance. Assigning the resistance to simple explanation that TRAIL cannot 
penetrate the colonospheres is therefore infirmed. In a recent similar study done on lung 
cancer A549 cell line, Yang (2009) not only neither assigned the resistance of spheroids to 
a limited diffusion of TRAIL, but suggested upregulation of anti-apoptotic Bcl-2 as a 
responsible mechanism. Another reason for the acquired resistance of spheroids to TRAIL-
induced apoptosis might be upregulation of the caspase-8 competetive inhibitor FLIP, as 
was recently documented in CD133-positive population of the breast carcinoma MCF-7 
(Zobalova et al., 2008). Further we must admit the possibility that signaling from EGFR 
alone may cause the resistance, since it was many times reported to have various profound 
anti-apoptotic effects (Akca et al., 2003). For example, in one such study EGF-mediated 
Mcl-1 upregulation was reported to block TRAIL-induced apoptosis (Henson et al., 2003). 
On the other hand, both signaling pathways from death receptors and EGFR appear to be 
very complex as documented in reports of EGF-induced apoptosis (Grudinkin et al., 2007; 
Zhao et al., 2006) or TNF induced survival mediated by EGFR (Yamaoka et al., 2008). 
Although multiple unknown regulatory knots remain to be solved in upcoming 
experiments, at this point we conclude that 3D spheroid model may be a better model for 
the multicellular resistance found in solid tumors than cells grown as monolayer.         
By observing that AC133 positive cell lines may be both highly (HCT 116) or less 
(HT-29A3) sensitive to TRAIL-induced apoptosis and vice-versa, we conclude that no 
simple correlation between the stem cell marker AC133 and TRAIL sensitivity was found, 
at least in our model colorectal carcinoma cell lines.  
In an attempt to even more mimicate the real tumor conditions, we assessed 
TRAIL-induced apoptosis of selected cancer cell lines co-cultivated with fibroblasts 
isolated from tumor stroma. The logical consequence with previous CSC context is 
retained, since Smetana’s group has recently shown that certain stromal fibroblasts may 
induce dedifferentiation in co-cultivated keratinocytes (Lacina et al., 2007). We have 
imitated their co-cultivation approaches and moreover developed our own direct 
co-cultivation system with use of RFP-labeled cancer cell line. At first, we observed that 
medium conditioned by normal fibroblasts (HF) and even more by fibroblasts from 
spinocellular carcinoma (S4) possibly inhibited TRAIL-induced apoptosis in HCT 116 and 
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DLD-1 cells. Such effect occurred mostly at TRAIL concentrations as low as 20ng/ml and 
was lost after 3 days, when conditioned medium was not exchanged. This may witness for a 
soluble factor that is either unstable or exhausted after three days.  Interestingly, similar 
effect we observed in direct co-cultivation of the same cancer cell lines, at least with S4 
fibroblasts. The fact that only at low concentration of TRAIL the effects were demonstrated 
seems logical. Indeed, the higher TRAIL concentration used (200 ng/ml) is artificial, and 
unlikely to ever occur in organism. Conversely, we have observed mild increases of cell 
death in TRAIL-untreated controls. Mainly after co-cultivation with B3 fibroblasts from 
basal cell carcinoma effects seemed ambiguous depending on whether direct co-cultivation 
or conditioned medium was used. Moreover, no influence of the feeder fibroblasts on 
TRAIL-induced apoptosis was reliably recognized in RFP-expressing DLD-1E8. In this 
particular case, however, the possibility that E8 clone has unique response, different of 
maternal cell line cannot be definitely excluded. It must be noted that all observed effects 
were minor and potentially bordering with statistical deviation, and we shall continue 
experiments to reliably address this potentially very interesting and important problems. 
Importantly, most of co-cultivation reports so far published was done in heterologous 
animal models, and even our setup is quite artificial. In future, we will therefore try to 
obtain stromal fibroblasts from colorectal carcinomas, as well as use the current fibroblasts 
in combination with cancer cell lines of different origin (e.g., breast, prostate and head and 
neck carcinoma). This approach should answer the question, if eventual influence of 
fibroblasts is panspecific or specific to tumor of origin. In conclusion, we have a clear 
motivation to continue in experiments since we believe in immense potential of 
co-cultivation studies, so far in their infancy. We have already tuned the co-culture 
protocols and set-up tools necessary for sophisticated flow cytomeric analyses. The fact 
that our current data are rather indistinctive does not discourage our efforts and even 
stimulates us to develop better experimental design utilizing experience from the so-far 
obtained results.  
 
Conclusions: 
 
 72
1. We have succesfully characterized a set of colon cancer cell lines and changes 
of their morphology, sensitivity to TRAIL-induced apoptosis, and expression 
of selected surface markers depending on cultivation conditions. 
 
2. We have observed that colon cancer cell lines were mostly uniform in their 
properties in vitro in relation to cancer stem cell model. Most of them posses 
uniform expression of putative CSC marker AC133, except for DLD-1 cell 
line with stable minor subset of AC133 positive cells. We have further 
observed correlation of AC133 phenotype and stem cell-like properties 
(sphere forming, apoptosis resistance). 
 
3. We have developed experimental design for direct co-cultivation of colon 
cancer cells with fibroblasts, (eventually with various cells of tumor stroma). 
 
  
4. We have shown that most of tested colon cancer cell lines were to some extent 
sensitive to apoptosis induced by TRAIL. Moreover, TRAIL agonistic 
receptors were upregulated after cultivation of cells in CSC-prone conditions. 
Paradoxically, apoptosis was mostly compromised despite the upregulation of 
death receptors.  
 
VI. Epilogue 
Respecting the fact that any game with the Occam’s razor is usually dangerous, 
author somehow doesn’t dislike being called heretic. Flipping through the results and 
myriads of literature on the topic, a repeated urging idea comes to his mind that something 
is overlooked in our very basic view of tumorigenesis. Irrespectively of whether clonal 
evolution or CSC theory or some kind of their mutual integration is favorized, we always 
assign the cancer causality to mutations. This belief, like most dogmas, is founded on lack 
of experimental evidence to the contrary. Author dares to claim, that regardless the well 
founded role of mutations, viewing cells in their social context is still much neglected. 
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Hence the role of cell communication in regulation of self-renewal symmetry, eventual 
induction of stem-cell properties and novel concepts of tumorigenesis represent the scaffold 
of author’s highest research priorities in possible future research career.          
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